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The main subject of this doctoral work is the role of the immune system in Alzheimer’s 
disease (AD), and how its understanding may help to develop novel diagnostic and 
therapeutic options for the disease.  
This study is structured in 2 parts, the first centred on mouse models of AD and in 
particular on the relationship between pathological features and inflammation in the brain 
of APPPS1/KI mice, while in the second part the focus is shifted on immune system 
involvement in human in vivo.  
The APP/PS1KI mouse model for AD has been previously shown to harbour severe 
pathological alterations, including behavioural deficits, axonal degeneration and 
hippocampal neuron loss starting at the age of 6 months. We observed early activation of 
the inflammatory marker GFAP already at 2 months, followed at 6 months by reduced 
levels of pre- and post-synaptic markers. Inflammatory processes are considered to play 
an important role in the progression of neurodegenerative changes in AD, and these data 
add further evidence to their association with axonal degeneration and neuron loss.  
 
It has previously been shown that immune complexes (IC) of a given biomarker with class 
M immunoglobulins (IgM) provide better performances compared to the unbound 
biomarker in a number of cancer entities. In the present work, we investigated IC of IgM-
Aβ as a potential biomarker for Alzheimer’s disease (AD). Aβ–IgM concentration has been 
measured in 75 plasma samples from patients with AD, individuals with mild cognitive 
impairment (MCI), and healthy age- and sex-matched controls (HC). Using an ELISA 
assay detecting Aβ–IgM complexes, we observed that high levels of Aβ–IgMs were 
detectable in HC and MCI patients; however, there was no significant difference to the AD 
group.  
To overcome the impossibility to discriminate IC of specific Aβ forms, we measured in the 
same plasma samples the level of IgM autoantibodies directed against different Aβ 
epitopes as potential diagnostic biomarkers for Alzheimer’s disease (AD). The mean level 
of anti-Aβ3(pE)-IgM was significantly decreased in AD patients compared to HC. In the 
group of MCI patients there was a significant positive correlation between anti-Aβ3(pE)-IgM 
and cognitive decline expressed as MMSE (rho = 0.58, df = 13, p = 0.022). These 
observations indicate that the level of IgM autoantibodies against Aβ3(pE) represents a 
 10
promising plasma biomarker for AD and correlates with the cognitive status of individuals 
at risk of developing AD. 
These data are in line with the idea of a possible pivotal role of Aβ3(pE) in AD development, 
as shown by a novel mouse model expressing only truncated Aβ3(pE)-42 demonstrating high 
neurotoxicity of this peptide. To better analyze pyroglutamate-positive plaque load in the 
brain, a novel monoclonal antibody highly specific for Aβ3(pE) has been developed.  
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1.1 ALZHEIMER`S DISEASE 
 
Alzheimer’s disease (AD) represents nowadays the most common form of senile 
dementia. AD is characterized by proceeding memory deficits and ongoing loss of daily-life 
abilities. First signs of the early disease state are short-term memory loss and visual-
spatial confusion, often accompanied by aphasia, disorientation or lack of inhibition. Many 
patients show changes in the way they approach their social surrounding with previously 
unknown violent outbursts or distinct passivity. Close relatives are normally the first to 
notice such changes in the character and behaviour of the person affected by AD and who 
is showing the first signs of cognitive impairment. As the disease progresses, together with 
proceeding cognitive decline, patients show also deterioration of musculature and a loss of 
mobility. Patients in the final stage are unable to perform even the simplest tasks, like 
walking or eating without assistance, suffer from incontinence of the bladder and/or the 
bowel, speak often in an utterly disorganized way and in the terminal phases require 
permanent supervision. This care is mostly achieved by close relatives of the demented 
persons; therefore, besides the aforementioned effects of AD on patients, it is in general 
the entire familiar environment which suffers the impact of AD, often pushing one family 
member to sign out of its job in order to assist the relative. Furthermore, most family 
members taking care of demented persons are themselves already in an advanced age 
and are therefore, due to their health conditions, not best suited to fulfil this task. 
Currently, an estimated 5.3 million Americans of all ages have Alzheimer’s disease, 
corresponding to one in eight persons aged 65 and older (13%). It has been estimated that 
the economic value of the care provided by family and other unpaid caregivers of people 
with Alzheimer’s and other dementias was $94 billion, which is the results of the average 
wage per hour of a caregiver. One study found that 87% of caregivers of people with 
Alzheimer’s and other dementias were taking care of a relative, and the remaining 13% 
were taking care of a non-relative, including a friend or neighbour (association 2009). 
 
 
1.2 CURRENT TREATMENTS FOR AD 
 
Despite the social benefit, but also the unquestioned economic potential that a treatment 
for AD would generate, there are to date no effective therapies on the market and likely 
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none is going to appear in the next few years. To date, only few medicaments are 
available for the treatment of AD; unfortunately, these drugs do not target the underlying 
disease mechanism but deliver only limited symptomatic benefits, with no overall 
slowdown in the progress of the disease. They are acetylcholinesterase (AChE) inhibitors 
and N-methyl-D-aspartate (NMDA) receptor antagonists. Briefly, since a reduced activity of 
cholinergic neurons has been observed in AD patients, which has been proposed to have 
some impact on the characteristically memory loss, drugs like Donepezil, Rivastigmine and 
Galantamine aim to stabilize levels of the neurotransmitter acetylcholine (ACh) in the 
brains by inhibiting AChE, the enzyme responsible for its degradation; however, these 
drugs only delay the first symptoms by some months. NMDA receptor antagonists like 
Memantine are based on the finding that in AD sustained activation of NMDA receptors 
may finally lead to the degeneration of cholinergic neurons. NMDA- receptor antagonists 
block the excessive glutamate-induced activation of the receptor that occurs under 
pathological conditions in AD (Hull et al. 2006).  
Epidemiological studies also suggested potential for non-steroidal anti-inflammatory drugs 
(NSAIDs), estrogens, HMG-CoA reductase inhibitors (statins) or tocopherol (vitamin E) to 
prevent AD. However, prospective, randomised studies have not convincingly been able to 
demonstrate clinical efficacy (Hull et al. 2006). Besides these therapeutic approaches a 
number of products has been suggested having beneficial properties against AD, including 
red wine for its content of flavonoids with antioxidant activity, omega-3-fatty acids, Gingko 
Biloba extracts, vitamins B and others, but none of these results has been confirmed 
(Morris 2009). However, what all these therapies and supplements lack is that they do not 
address the underlying disease pathomechanism . 
Given the substantial failure of previous drugs, a new generation of pharmacological 
treatments is being developed. They have the potential to halt the progression of AD 
because they are aimed to directly lower the neurotoxic effects of the amyloid-β (Aβ, see 
below) peptide rather than just targeting the symptoms of the disease by restoring the 
activity of altered neurotransmitter function. So far, several approaches to modulate Aβ 
metabolism have been tried, with varying success. The most renown, and initially most 
promising, was the Aβ active vaccination trial AN-1792 in 80 people with AD; however, this 
trial was stopped early after 6% of the participants developed meningoencephalitis. 
Although there was no overall improvement in clinical profile in patients who received this 
active immunization, clearance of amyloid plaques in the brain did occur and, despite the 
effect being independent of antibody response, this trial provided an important proof of 
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concept (Holmes et al. 2008). Passive immunization with humanised monoclonal 
antibodies with specificity to Aβ peptides might potentially reduce side-effects, but on the 
other hand it presents issues relative to its multiple dosing, including lower patients 
compliance and potential overdose risks. However, immunotherapy is a promising strategy 
and several treatments are currently under clinical development, including antibodies with 
different specificities and of different classes. 
Another category of second generation medicaments for AD aims to the modification of the 
amyloid metabolic pathway. PBT2 is a metal-protein-attenuating compound that affects 
copper-mediated and zinc-mediated toxic oligomerization of Aβ. In a randomised placebo-
controlled study of 78 patients with PBT2 (Lannfelt et al. 2008), no serious adverse events 
were seen; compared to the placebo group, the treated group showed a significant dose-
dependent decrease in cerebro-spinal fluid (CSF) Aβ coupled to an improvement in 
cognition in two tests of executive function. A trial with another anti-Aβ drug, tarenflurbil 
(flurbiprofen), showed a decrease in Aβ production with a good tolerance, and evidences 
of a dose-related effect on measures of daily activities and global function in 210 people 
with mild AD, however without any effect on people with moderate AD (Wilcock et al. 
2008).  
Dimebon, a non-selective antihistamine, has shown positive effects on both cognition and 
activities of daily living, with improvements at 12 months and a low incidence of side-
effects in a study of 183 people with AD (Doody et al. 2008).  
In any case, in order for these drugs to be successful, they should be given at the earliest 
stages of the disease—possibly before symptoms appear. Thus, the facility to identify 
people at risk or to diagnose AD at an early stage is essential. It is, in fact, becoming more 




1.3 AD PREVENTION 
 
Prevention in AD acquires great importance if we consider the extremely long 
asymptomatic latent period of this disease. Even an intervention that delayed disease 
onset by just a few years could dramatically reduce the burden of this disease on society 
and public health-care systems (Brookmeyer et al. 1998). To this end, there has been 
recently great focus on the identification of potential preventive factors for dementia, and 
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epidemiologic research has suggested various candidates, including modifiable lifestyle 
factors, such as social contacts, leisure activities, physical exercise, and diet, as well as 
some pharmacologic strategies, such as hormone replacement therapy, NSAIDs, and 
Ginkgo biloba. In addition, the treatment of vascular risk factors could be important. Some 
of these factors have been targeted by interventions tested in randomized controlled trials, 
but many of the results obtained are in conflict with those obtained in observational studies 
(Hull et al. 2006). 
A preventive strategy based on the use of a pharmacologic treatment would seem to be a 
relatively simple method of preventing AD. Since an extremely high number of people 
would be exposed to the treatment without ever developing AD, a good risk-benefit ratio 
would be necessary. Until such a treatment will be discovered, lifestyle factors (diet, social 
engagement, cognitive stimulation, physical exercise) seem the most reasonable 
candidates for prevention trials at the current time, in particular because of their safety. 
Because of the difficulties in conducting multi-domain intervention, randomized controlled 
trials would not represent an cost-effective and thus economically-appealing approach, 
and large public health interventions at the population level could be required. However, 
such interventions would have to be feasible, cost effective, and easily transferable in 
order to have a real public health impact (Coley et al. 2008). In addition, the best results 
from an effective prevention strategy would be obtained by having at disposal a reliable 
method for early diagnosis. tToday many CSF biomarkers with a good diagnostic value 
exist to predict the onset of AD; unfortunately, CSF measurement is a painful and invasive 
exam, inappropriate to be used as mass-screening method. For this reason, other more 
accessible biological fluids are being examined for the presence of new potential 
biomarkers, but the results have been so far contradictory and not satisfying. More 
sophisticated diagnostic criteria need to be established that take into account the potential 
of current diagnostic biomarkers, whether they are in the blood, cerebrospinal fluid, or 
visualised by Positron Emission Tomography (PET) brain imaging (Dubois et al. 2007).  
 
 
1.4 FAMILIAL AND SPORADIC TYPE OF AD 
 
There are 2 different forms of AD: familial or early-onset AD (FAD) and sporadic or late-
onset-AD, the latter representing the vast majority of the total cases. 90-95% of AD cases 
are, in fact, sporadic with proceeding age as the major identifiable risk factor, while only 5-
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10% of the disease cases are genetically based (Tanzi 1999). FAD is caused by Mutations 
associated with the genes encoding the amyloid precursor protein (APP, chromosome 21), 
Presenilin-1 (PS1, chromosome 14), and Presenilin-2 (PS2, chromosome 1) (Fig. 1). 
These mutations foster abnormal processing of APP and therefore lead to overproduction 
of the most common Aβ peptides Aβ1-40 and Aβ1-42. Additionally, the 4 allele of 
apolipoproteinE (ApoE) has also been shown to be associated with an increased risk for 
late-onset AD (St George-Hyslop 1999; Lambert et al. 2009).  
However, the causes of sporadic AD, besides ageing, remain uncertain, though extensive 
research efforts are being made which address this issue. Widely discussed is the 
influence of environmental agents (e.g., heavy metals), intrinsic factors (e.g., cytokines), 
and dietary factors (e.g., cholesterol) (Lahiri et al. 2007). 
 
Figure 1 (A) Missense mutations in the APP gene (HCHWA-D: amyloidosis Dutch type; FAD: familiar Alzheimer 
disease). Data taken from (St George-Hyslop 2000) (B) Genetic mutations implicated in familiar or sporadic onset of 
Alzheimer’s disease (according to (St George-Hyslop 1999)). 
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1.5 NEUROPATHOLOGICAL HALLMARKS OF ALZHEIMER`S DISEASE 
IN HUMAN 
 
Neuropathologically, brains of AD patients are characterized traditionally by the presence 
of senile plaques consisting of Aβ and neurofibrillary tangles of hyper-phosphorylated tau-
protein. Functionally, the brain presents extensive neuron loss, synaptic dysfunction, 
vascular deficits and inflammation. 
 
 
1.5.1. Aβ PRODUCTION 
 
Aβ is produced in the brain by enzymatic cleavage of the transmembrane protein APP 
(Gandy et al. 2000). APP mRNA alternative splicing produces at least 8 distinct isoforms, 
namely APP677, APP695, APP696, APP714, APP733, APP751, APP752 and APP770, 
APP695 being the most common isoform in the brain (Golde et al. 1990; Sandbrink et al. 
1997). 
APP processing leads to the production of different fragments, depending on distinct 
secretases acting on it. In the non-amyloidogenic, non-pathogenic pathway APP is cleaved 
first by the enzyme α-secretase, leading to the release of sAPPα, and subsequently by γ-
secretase, which produces the N-terminally truncated Aβ fragment “p3”(Carter et al. 2001). 
α-secretase cleaves APP within the Aβ sequence at position 17, therefore p3 represents 
the fragment Aβ17-40/42. As a consequence, α-cleavage of APP prevents the formation of 
Aβ1-40/42 which are the most prominent Aβ-species in AD affected brains. The identity of α-
secretase and its mechanism of regulation remains unclear; main candidates are the 
ADAM family of proteases (A Disintegrin And Metalloprotease) members ADAM9, 10 and 
17 (Hiraoka et al. 2007). 
In the amyloidogenic pathway, APP is initially cleaved by β-secretase and the sAPPβ 
fragment is released; the remaining transmembrane peptide C99 is then processed by γ-
secretase leading to the generation of Aβ (Van Broeck et al. 2007). β-Secretase has been 
reported to be a type I transmembrane glycosylated aspartyl protease, while γ-secretase is 
a high-molecular-weight protein complex comprising at least the four proteins Aph-1, Pen-
2, nicastrin and PS1/2, with the latter containing the active site (Guntert et al. 2006; Van 
Broeck et al. 2007). Though the exact intracellular cleaving sites of γ-secretase and the 
nature of this enzyme are still not fully understood, it is commonly accepted that γ-
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secretase cleavage of C99 produces peptides of different lengths, the most prominent of 
which are Aβ1-40 and Aβ1-42 (Carter et al. 2001) (Fig. 2). 
 
 
Figure 2 Non-amyloidogenic and amyloidogenic pathway of APP processing by subsequent proteolytic cleavage by α-




The cleavage sites of the enzymes involved in APP processing are all near to or at those 
positions in the APP sequence where FAD mutations have been found (Fig. 3); as a 
consequence, all FAD mutations in the genes for APP, PS1 and PS2 result in increased 
production of Aβ. Notably, mutations in PS1 and PS2 have been shown to enhance the 
production of Aβ1-42 in vitro and in vivo (Xia 2000; Takeda et al. 2004). While Aβ1-40 in 
human AD patients is the far most abundant Aβ species with an estimated 1000-fold 
excess compared to Aβ1-42, the latter one has been shown to be much more prone to 




Figure 3 Schematic representation of the APP protein, including the Aβ sequence, cleavage sites of α-, β-, and γ-
secretase, important mutations in the APP protein related to familial AD and binding sites of important antibodies. 
 
 
1.5.2. Aβ PLAQUE DEPOSITION 
 
The formation of senile plaques consisting mainly of Aβ peptides is the most evident 
hallmark of AD brains. It is widely accepted that production and aggregation of Aβ is a key 
event in the pathology of AD (Van Broeck et al. 2007).  
The molecular mechanism with which Aβ initiates neurodegeneration remains so far 
unknown. Until recently, it was common knowledge that extracellular insoluble Aβ plaques 
were directly responsible for neuron loss and AD development, but recent evidences point 
to intracellular Aβ as being the actual main toxic agent (see (Tseng et al. 2004; Wirths et 
al. 2004) for review). This revised version of the amyloid hypothesis is based on the finding 
that Aβ accumulation initiates in the intraneuronal space while extracellular formation of 
plaques is a subsequent event (Masters et al. 1985; Wirths et al. 2004) (Fig. 4).  
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Figure 4 Two versions of the Amyloid hypothesis: Sequence of pathogenic events leading to AD pathology is shown in 
the classical understanding according to Hardy et al. (right part of figure) and in a revised version according to Wirths et 
al. (left part of figure) that focuses on the contribution of intraneuronal accumulation of Aβ42 to the development of AD 
pathology. Both vicious cascades may interfere and contribute in parallel as well to the cognitive decline symptomatic 
for AD affected patients, as suggested by horizontal arrows. 
 
 
The rationale for this hypothesis was the observation of deficits in behaviour, synaptic 
transmission and long-term potentiation well before first signs of plaque pathology in 
several transgenic mouse models of AD (Holcomb et al. 1998; Hsia et al. 1999; Moechars 
et al. 1999). The hypothesized pathological role of intracellular Aβ was supported by the 
finding, among others, that this pool of Aβ represents an early and integral component of 
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the pathogenesis of the human muscle disorder IBM (inclusion body myositis) (Mendell et 
al. 1991; Askanas et al. 1993). Additionally, immunohistochemical analysis of human 
postmortem brain and APP/PS1 transgenic mouse brains clearly showed an age-
dependent increase of Aβ1-42 -species within neurons (Gouras et al. 2000; D'Andrea et al. 
2001; Busciglio et al. 2002; Tabira et al. 2002; Wirths et al. 2004). The importance of 
intracellular Aβ has been supported by several recent studies ((Glabe 2001; Gouras et al. 
2005) for a review). Most convincing, in an APP/PS1KI mouse model of AD a strong 
correlation between early accumulation of intraneuronal Aβ in CA1/2 region of the 
hippocampus starting already at 2 months of age and extensive neuron loss (~50%) in this 
area of the hippocampal pyramidal cell layer was reported (Casas et al. 2004). 
Furthermore, it is now generally accepted that Aβ is most toxic in a soluble, oligomeric 
aggregation state (Fig. 5), rather than aggregated β-sheet-containing amyloid fibrils 
(Selkoe 2001; Klein 2002). It has been demonstrated that soluble oligomeric Aβ42, and not 
amyloid plaques, correlates best with cognitive dysfunction in AD (McLean et al. 1999; 
Naslund et al. 2000), and oligomers are formed preferentially within neuronal processes 
and synapses rather than extracellularly (Walsh et al. 2000; Takahashi et al. 2004). 
Recently, our group also reported that transient intraneuronal Aβ rather than extracellular 
plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice 
(Christensen et al. 2008). 
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Figure 5 Possible pathways for plaque formation highlighting the different phases and aggregation states. Although 
mature fibrils, which eventually aggregate into plaques, are the endpoint of the process, it is not clear yet which Aβ 




1.5.3. NEUROFIBRILLARY TANGLES 
 
Brain neurofibrillary tangles (NFT) represent, together with amyloid plaques, the two 
characterizing hallmarks of AD. NFTs appear as bundles of abnormal filaments called 
paired helical filaments (PHF), composed of highly phosphorylated forms of the ~55 kDa 
microtubule-associated protein tau. It is commonly accepted that the high degree of 
phosphorylation of PHF-tau leads to microtubule disorganization and the generation of 
neurofibrillary lesions (Boutajangout et al. 2002). Six tau isoforms generated by alternative 
splicing of tau RNA are known in the human brain (Wagner et al. 1996). Tau protein binds 
and stabilizes microtubules and promotes microtubule assembly in vitro (Goedert et al. 
1990); it is therefore believed to have an active role in the formation and maintenance of 
axons. In this regard, it has been shown that antisense oligonucleotides down-regulating 
tau expression in primary cerebellar neurons impair the generation of new axons (Wagner 
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et al. 1996). The phosphorylation process of tau takes place at serine/threonine residues 
preceding a proline and is mediated by a number of proline-kinases including e.g. 
members of the mitogen-activated protein kinase (MAPK) family, glycogen synthase 
kinase 3α (GSK3α) and 3β (GSK3β) or Cyclin-dependent kinase 5 (CDK5). At a cellular 
level, hyperphosphorylated tau is mostly found in the somatodendritic compartment of the 
neurons (Zheng et al. 2002) (Fig. 6). 
 
 
Figure 6 Tau malfunction in AD: In a healthy neuron (top), tau stabilizes the microtubules (blue lines) that transport 
materials to the nerve terminals. In AD, tau is unable to bind to the microtubules and forms abnormal aggregates, the so 
called paired helical filaments (PHF-tau). This process fosters degeneration of microtubules and induces impaired 
neuronal functioning (graphics taken from Marx 2007). 
 
 
The precise pathophysiology of tau is still a matter of discussion. Rapoport et al. reported 
in vitro Aβ-induced neurotoxicity initiated by tau: incubation of fibrillar Aβ with cultured 
hippocampal neurons expressing either mouse or human tau showed clear signs of 
neurodegeneration, while no such effect was observed in tau-knockout mice under the 
same conditions (Rapoport et al. 2002). On the other hand, Zheng et al. demonstrated in 
vitro, that Aβ can induce tau hyperphosphorylation in rat primary septal cultures (Zheng et 
al. 2002). Microtubular destabilization provoked by hyperphosphorylated tau aggregates 
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has been speculated to lead to impairment of cellular transport, (Mandelkow et al. 2003), 
cellular geometry, and neuronal viability (Cummings et al. 1998). 
 
 
1.5.4. HIPPOCAMPAL SHRINKAGE, NEURON LOSS AND SYNAPTIC DEFICITS 
 
In AD patients, synaptic density decline in the brain appears to be the pathological 
hallmark that best correlates with the extent of cognitive loss during the disease 
development, if compared to plaque pathology, NFTs, neuron loss, and neurotransmitters 
deficits (Coleman et al. 2003). 
Two independent studies revealed a correlation coefficient of 0.7 between synapse density 
and cognitive status of AD patients (Coleman et al. 2003). In well accordance with the 
event of synapses loss, Reddy et al. analyzed levels of synaptic proteins in brains of AD 
patients and reported a loss of pre-synaptic proteins (synaptotagmin, synaptophysin, and 
Rab3A), synaptic membrane proteins (Gap43 and synaptobrevin) and post-synaptic 
proteins (neurogranin and synaptopodin) in AD patients when compared to healthy 
controls (HC) (Reddy et al. 2005). Synaptic decline appeared to be more severe in the 
frontal cortex compared to the parietal cortex of AD patients (Reddy et al. 2005). 
Neuron loss in AD represents a further marker of cognitive decline. Shepherd et al. 
reported a neuron loss in frontal superior cortex of 36% in early onset AD cases and of 
22% in sporadic AD cases compared to HC (Shepherd et al. 2007). In patients with mild 
AD a 32% neuron loss has been observed in the entorhinal cortex (EC), an area of the 
cortex believed to have a crucial role as a gateway connecting the neocortex and the 
hippocampal formation. The EC receives afferents from widespread association cortex and 
limbic areas, projects to the dentate gyrus of the hippocampal formation, receives afferents 
from the hippocampus, and sends afferents back to association neocortex. The EC is a 
region highly vulnerable in AD and layers II and IV of the EC have been shown to be 
among the first regions affected with tangles in Down syndrome and in normal aging. In 
severe cases of AD, a decrease in the neuron number of up to 90% was measured in layer 
II and of up to 70% in layer IV when compared with HC, whose neurons number remained 
constant between 60 and 90 years of age (Gomez-Isla et al. 1996). 
The hippocampal formation of the brain is the region that shows the most prominent 
atrophic changes caused by AD. In an MRI analysis of AD patients brain Bobinski et al. 
found a decline of hippocampus volume of about 30% compared to HC (Bobinski et al. 
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2000). Several MRI-based studies indicate hippocampal atrophy as a relatively specific 
early stage marker of AD (Bobinski et al. 2000; Jack et al. 2002; Silbert et al. 2003), and a 
strong correlation between hippocampal atrophy and cognitive decline has also been 
reported (Petersen et al. 2000; Jack et al. 2002; Chetelat et al. 2003). On the other hand, 
other studies suggest MRI-assessment of EC volume as a more suitable marker for 
diagnosis of early stage AD compared to hippocampal volume, allowing also better 
differentiation between mild cognitive impairment (MCI) and early stage of AD (Pennanen 
et al. 2004). 
It is well established that APP undergoes fast axonal transport (Koo et al. 1990) and plays 
an important role in axonal and synaptic processes physiology. Abnormal focal axonal 
swellings, that correspond to pathological accumulation of axonal cargoes and transport 
proteins, are evident in AD brains (Stokin et al. 2005). Recently, axonal deficits and 
degeneration have been described in AD (Dai et al. 2002) and in different APP transgenic 
mouse models overexpressing human APP in brain and spinal cord (Stokin et al. 2005; 
Wirths et al. 2006) including APP/PS1KI mice (Wirths et al. 2006). These axonal 
alterations are visible as varicosities and spheroids, containing abnormal accumulations of 
mitochondria and other organelles together with axonally-transported material like 
neurofilaments, synaptic proteins and APP. Stokin et al. have pointed out that inhibition of 
axonal transport leads to increased intraneuronal Aβ accumulation (Stokin et al. 2005). 
Interestingly, intraneuronal Aβ accumulation precedes axonal degeneration in APP/PS1 
models (Wirths et al. 2006), where aberrant intraneuronal Aβ accumulation coincided with 
impaired axonal integrity (see APP/PS1KI chapter).  
 
 
1.5.5. BRAIN INFLAMMATION 
 
Neuropathological and neuroradiological studies have demonstrated that inflammatory 
processes, like microglia activation and astrocyte reactivity, occur early during the course 
of the disease (reviewed in (Eikelenboom et al. 2006). These processes are widely thought 
to be triggered by plaques and tangles formation (Arnaud et al. 2006). For example, 
reactive microglia surrounding senile plaque cores have been consistently reported in AD 




Figure 7 Clusters of HLA-DR immunoreactivity in gray matter of AD cortex are highly correlated with AD pathology. 
A1,B1 HLA-DR positive clusters, bright field optics (200 x). A2,B2 The same fields with dim bright field and 
thioflavin S fluorescence showing plaque cores. C1,C2 Unlike plaques, which co-localize almost universally with 
HLA-DR positive clusters, neurons filled with neurofibrillary tangles (arrowheads) sometimes co-localize with HLA-
DR clusters and cells, but sometimes do not. Large, unravelling tangles appear most vulnerable. Panel C1 is 
fluorescence only. Panel C2 adds dim bright field (200x) (Rogers et al. 1988) 
 
 
While the event of inflammation in the brain was formerly believed to be a peripheral 
phenomenon of the disease, the hypothesis of neuroinflammation as one of the potential 
triggers for neurodegeneration and other pathological hallmarks of AD today is gaining in 
acceptance (Streit et al. 2004; Arnaud et al. 2006); however, the putative associations and 
causative links between these AD hallmarks have not been fully elucidated.  
The importance of inflammation in the pathogenesis of AD was indirectly confirmed by 
epidemiological investigations that revealed a decreased incidence of AD in subjects using 
anti-inflammatory drugs, especially NSAIDs (Wyss-Coray 2006). However, clinical trials 
designed to inhibit inflammation have failed in the treatment of AD patients suggesting that 
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anti-inflammatory agents have more protective than therapeutic effect. Despite ongoing 
research, the extent to which neuroinflammation contributes to disease pathogenesis is 
still not fully understood. Moreover it is also not clear whether inflammation in AD brains 
represents a protective reaction to neurodegeneration or if it is rather a destructive process 
that contributes to further loss of brain function (Akiyama et al. 2000). 
 
 
1.6. MODELLING OF HUMAN AD-LIKE FEATURES IN TRANSGENIC 
MICE 
 
1.6.1. OVERVIEW OF AD TRANSGENIC MOUSE MODELS  
 
Transgenic mouse models are valuable tools to study the aetiology of human disorders, 
including AD; they have greatly contributed to our understanding of its pathogenesis. 
Whereas the majority of all AD cases occurs sporadically, a small percentage of familial 
early-onset AD cases develops due to mutations of APP or Presenilin (reviewed in (Bayer 
et al. 2001)); transgenic mouse models generally are based on these mutations. Many 
models have been described so far that display to a higher or lower extent the 
neuropathological features typically seen in AD cases: early pathological changes, such as 
deficits in synaptic transmission (Hsia et al. 1999), changes in behaviour, differential 
glutamate responses, learning deficits and deficits in long-term potentiation were all 
reported in several mouse models for AD overexpressing APP (Holcomb et al. 1998; 
Moechars et al. 1999; Puolivali et al. 2002; Billings et al. 2005; Oakley et al. 2006). 
However, Aβ deposition did not correlate with the behavioural phenotype (Holcomb et al. 
1999); moreover, none of them exhibits all AD-typical hallmarks alone. 
Typically, mouse models overexpressing mutant human APP (hAPP) show increased 
production of Aβ and reveal a more or less severe pattern of diffuse or compact amyloid 
plaques in immunohistochemical staining. These mice display also synaptic transmission 
deficits detectable well before the build-up of massive plaque pathology. Some of these 
APP-based models also display features like neurodegeneration or cognitive deficits. Early 
pathological alterations before onset of plaque deposition that might be related to 
intraneuronal Aβ accumulation have also previously been reported in other mouse models. 
These include deficits in synaptic transmission (Hsia et al. 1999) or changes in behaviour 
and deficits in long-term potentiation (LTP) (Moechars et al. 1999). 
 32
Other mice models contain a human mutant tau transgene as can be found in familial 
forms of fronto-temporal dementia (FTD), where extensive tangle formation is a dominant 
feature. Oddo et al. developed a triple-transgenic mouse model, harbouring mutant 
transgenes for tauP301L, APPK670N,M671L and PS1M146V. This model shows plaque 
pathology, tangles and also displays synaptic transmission deficits (Oddo et al. 2003).  
Until recently, however, modelling axonal degeneration and neuronal loss remained 
elusive. APP23 transgenic mice presented a small loss of pyramidal neurons of the 
hippocampal formation (Calhoun et al. 1998), which did not reflect the dramatic reduction 
in AD patients (Gomez-Isla et al. 1996). Recently, mouse models carrying both APP and 
PS1/2 transgenes have been shown to further increase Aβ production and to significantly 
accelerate the development of AD-like phenotype and pathology. Mild neuron loss has 
been documented around amyloid plaques in PSAPP mice (Urbanc et al. 2002). Moreover, 
2 different mouse models carrying multiple mutations in the PS1 and APP genes have 
been described that present significant neuron loss in the hippocampus (Casas et al. 
2004; Schmitz et al. 2004).  
Schmitz et al. crossed human APP751 transgenic mice harbouring the Swedish and 
London mutations (APP751SL) with the human mutant PS1 (M146L) transgenic line. The 
hAPP gene was under control of the THY1 promoter, which drives gene expression 
specifically in neurons. In 17 month-old APP/PS1 M146L mice a 25% reduction of CA1-3 
neurons compared to age-matched control mice has been observed, a reduction larger 
than what could be explained only by amyloid plaque pathology (Schmitz et al. 2004).  
Casas et al. used the same APP751SL mice, but crossed them with PS1 knock-in (PS1KI) 
mice harbouring two human PS1 mutations (M233T/L235P) in the endogenous mouse 
PS1 gene; thus, expression of mutated PS1 takes place under control of the endogenous 
promoter. These mutations were specifically selected because of their link to very early 
onset FAD at 29 (L235P) and 35 (M233T) years of age. This model, named APP/PS1KI, 
displays at 10 months a neuron loss of over 50% in the CA1 region, and the 
histopathological onset of AD-like features is evident already at 2 months of age with 
massive accumulation of intraneuronal Aβ (Casas et al. 2004).  
In the next paragraph, the focus will be on this latter model, which is the main model used 





1.6.2. THE APP/PS1KI MOUSE MODEL 
 
Due to the London mutation, which increases the affinity for gamma-cleavage at position 
42, the predominant species of Aβ in these mice is Aβ42. However, after measurement of 
total Aβ, a relative share of Aβ42 of 85% was determined at 4 months, while 4 months old 
APPSL littermates revealed only a 30% on the total Aβ plaque composition of this form. 
This indicates that the presence of FAD-linked PS1KI mutations in APP/PS1KI mice 
contributes significantly to the formation of Aβ42. APP/PS1KI mice display widespread and 
numerous round compact Aβ deposits within the subiculum, cortical, hippocampal, and 
thalamic areas, starting at 2.5 months, unlike APPSL mice, which show only very few 
deposits restricted to the areas of the subiculum and deeper cortical neuronal layers with a 
delayed onset at 6 months of age. 
Detailed analysis of the hippocampal CA1-3 subfield and of the dentate gyrus showed that 
APP/PS1KI mice display a significant reduction of the hippocampal pyramidal cell layer 
thickness, this being particularly prominent in the CA1 region in 6 months old females, 
which showed a neuron loss of 33%. Neuron loss was detected to take place in the CA1/2 
pyramidal cell layer of the hippocampus to an extent of 50% at 10 months of age with a 
macroscopically evident loss already at six months of age (Casas et al. 2004) (Fig. 8). 
 
 
Figure 8 APPSLPS1KI transgenic mice develop massive neuronal loss in the hippocampus. A Representative 
photomicrographs of cresyl violet-stained sagittal brain sections of 10-month-old PS1KI, APPSL, and two 
APPSLPS1KI mice at low magnification. Note the deeply reduced thickness of the CA1/2 pyramidal cell layer 
indicated between arrows in the APPSLPS1KI brain (bottom). B Higher magnification views of the cresyl violet-stained 
CA1/2 subfield of a representative APPSL (top) and APPSLPS1KI (bottom) mouse are shown. C APP immunostaining 
of the hippocampal formation in 2 (top)- and 10 (bottom)-month-old APPSLPS1KI mice. APP staining reveals a very 
strong APP expression in CA1/2 subfield with a faint labelling in CA3 where no neuronal loss was detected. Note again 
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the reduced thickness of CA1/2 subfield with the APP neuronal immunostaining. Scale bars: 150 _m (A); 50 _m (B); 
100 _m (C). Figure from (Casas et al. 2004). 
 
 
APP/PS1KI mice showed also prominent axonopathy: immunohistochemical and 
ultrastructural analysis by electron microscopy in APP/PS1KI mice revealed age-
dependent characteristic axonal swellings, spheroids, axonal demyelination and ovoids, 
which are myelin remnants of degenerated nerve fibers (Wirths et al. 2007) (Fig. 9). 
Generally, plaque pathology in APP/PS1KI mice is preceded by the accumulation of 
oligomeric and fibrillar Aβ deposits in brain and spinal cord motor neurons in young mice; 
many of these peptides present various N-terminal modifications like truncations and N-




Figure 9 Electron micrographs and semithin spinal cord white matter sections of 10-month-old APP/PS1KI mice. 
Dilated axons demonstrating an accumulation of mitochondria and various dense vesicles (A and B). Macrophage 
containing phagocytosed axonal material (arrowheads), representing myelin ovoids (C). Toluidine blue stained sections 
of the cervical spinal cord with numerous white matter ovoids in a 10-month-old APP/PS1ki mouse (D), whereas 
PS1KI mice were almost devoid of myelin ovoid pathology (E). Quantification revealed a significant increased density 
of profiles of white matter ovoids in APP/PS1KI mice compared to PS1ki control mice (F). Error bars, S.E.M.; ***P < 
0.001. Scale bars: (A) 7.5µm; (B) 2.5 µm; (C) 5.5 µm; (D and E) 33 µm (Wirths et al. 2007) 
 
 
1.6.2.1. RELATED SIDE PROJECT: AD-LIKE RELEVANT FEATURES IN 
TRANSGENIC MOUSE MODELS 
 
The APP/PS1KI mouse model has been shown to harbour deficits in cognitive and motor 
performance already at the age of 6 months (Wirths et al. 2008), with extensive loss of 
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CA1 pyramidal neurons quantifiable in 50% at 10 months of age (Casas et al. 2004), 
accompanied by severe axonal degeneration (Wirths et al. 2007). This is the only mouse 
model so far, developing abundant hippocampal neuron loss within the age of 1 year 
(Casas et al. 2004). 
Successively to intracellular accumulation of Aβ, six-months-old APP/PS1KI mice show 
abundant extracellular plaques harbouring a broad variety of N-truncated Aβ, dystrophic 
neurites and astrogliosis (Casas et al. 2004). APP/PS1KI mice have a good resemblance 
of pathological and behavioural hallmarks with the actual disease, therefore they represent 
a suitable model for studying human-like AD-pathological processes.  
Since no neuron loss and no behavioural phenotype was detected in these mice at 2 
months of age compared to age matched PS1KI control mice a systematic analysis of 
various inflammatory and synaptic markers has been performed in pre-symptomatic (2-
month-old) and affected APP/PS1KI mice (6-month-old).  
 
Inflammation 
Though the occurrence of neuroinflammatory events represents a phenomenon well 
described in AD, the extent to which and the way how inflammatory processes are 
involved with the pathology of the disease are still a matter of debate. It is often suggested 
that Aβ plaques, tangles and the event of neurodegeneration with the exposition of 
intracellular DNA and neurofilaments to the extracellular environment are the main triggers 
for the activation of several generic inflammatory pathways in human brains affected by 
AD. 
Inflammatory changes have been previously described in a variety of different APP 
transgenic mouse models (Benzing et al. 1999; Stalder et al. 1999; Mehlhorn et al. 2000; 
Apelt et al. 2001; Bornemann et al. 2001; Qiao et al. 2001; Richards et al. 2003; Heneka et 
al. 2005). Additionally, this lab performed an extensive and detailed study on APP/PS1KI 
mice which included a broad range of inflammation markers (Fig. 10) like cytokines and 
cytokine receptors, toll-like receptors, transcription factors and acute phase proteins, as 
well as proteins involved in metal homeostasis and oxidative stress defence like the 




Figure 10 Quantitative real-time PCR shows consistent activation of microglia markers F4/80 and CD11b, members of 
the Toll-like receptor family (Tlr2, Tlr4, Tlr7, Tlr9) representing innate immune receptors, as well as for MCSFR and 
MSR2 at the age of 6 months on APP/PS1KI mice compared to their PS1KI littermates. In addition, Cathepsin D levels 
were significantly increased at both 2 and 6 months of age, indicating early microglial activation. Figure from (Wirths 
et al. 2008).  
 
 
The scope of this side project was to relate specific phases of inflammation to specific 
phases of the pathological processes connected to AD by measuring the expression of an 
inflammation protein marker, GFAP, in young, asymptomatic -month-old mice and 
diseased 6-month-old mice. Since the causality relationship between AD and inflammation 
is still unclear, a closer look to the temporal order by which changes in the expression of 
inflammatory genes take place in relation to the uprising of typical AD pathological 
characteristics is of interest. Such information may help to spread light over the matter of 
whether inflammation of the brain is a side effect of AD pathology or whether inflammatory 
processes may contribute to the progress of cognitive decline in AD patients. 
 
Synaptic deficits 
It is well established that AD patients suffer from working memory deficits (Baddeley et al. 
1991). However, motor performance deficits have also been described to occur in AD 
patients e.g. gait disturbances, disturbed activity level and balance, as well as general 
motor signs (Alexander et al. 1995; O'Keeffe et al. 1996; Pettersson et al. 2002; Scarmeas 
et al. 2004). 
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APP/PS1KI mice develop severe age-dependent axonal degeneration (Wirths et al. 2006) 
(Fig. 9), as well as loss of hippocampal CA1/2 neurons starting at the age of 6 months 
(Casas et al. 2004). In addition, deficits in induction of long-term synaptic changes have 
also been observed (Breyhan et al. 2009).  
Recently, it is becoming widely accepted that the soluble oligomers and the β-sheet 
containing amyloid fibrils are the toxic forms of Aβ (Selkoe 2001; Klein 2002; Harmeier et 
al. 2009). Considering that oligomers are formed preferentially within neuronal processes 
and synapses rather than extracellularly (Walsh et al. 2000; Takahashi et al. 2004), the 
aim of the present study was to investigate and quantify how some synaptic markers are 





One of the most coherent arguments pointing against the Amyloid hypothesis is the finding 
of Aβ plaques in the brains of elderly subjects without any sign of cognitive decline. It has 
been speculated that the difference between AD patients and plaques-bearing HC is to be 
searched in the plaques composition, rather than in the sheer presence of plaques (Piccini 
et al. 2005). Differences in the Aβ species composing plaques have been described 
repeatedly over the years. It is an established fact that amyloid plaques do not consist only 
of full length, unmodified Aβ1-40 and Aβ1-42, but rather of a mix of Aβ peptides of different 
lengths,  often bearing post-translational modifications. 
In fact, besides Aβ peptides starting with an aspartate at position 1, a variety of different N-
truncated Aβ peptides have been identified in AD brains. Truncated peptides in majority 
beginning with phenylalanine at position 4 of Aβ have been reported as early as 1985 by 
Masters et al. (Masters et al. 1985). In contrast, no N-terminal sequence could be obtained 
from cores purified in a sodium dodecyl sulfate-containing buffer, which led to the 
assumption that the N-terminus could be blocked by a post-translational modification 
(Gorevic et al. 1986; Selkoe et al. 1986). 
Initial difficulties in sequencing Aß peptides purified from human brain tissue were in part 
explained by the presence of N-terminal truncated Aβ starting with pyroglutamate (Aβ3(pE)) 
shown using mass spectrometry of purified Aβ peptides (Mori et al. 1992). Saido and co-
workers (Saido et al. 1995) showed then that Aβ3(pE) represents a dominant fraction of Aβ 
peptides in senile plaques of AD brains and hypothesized a mechanism in which Aβ3(pE) 
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aggregation precedes and works as a seed for the aggregation of the other Aβ species, 
due to its higher hydrophobicity (Saido et al. 1996). This was later confirmed by other 
reports investigating AD and Down’s syndrome post-mortem brain tissue; in particular, 
Iwatsubo et al. reported massive aggregation of AβN1(L-isoAsp), AβN1(D-Asp), and of Aβ3(pE). 
Additionally, weak staining patterns were detected for pyroglutamate AβN11-42(pE) and for 
AβN17(Leu) (Iwatsubo et al. 1996). Lemere et al. reported in 29-year-old Down’s Syndrome 
patients a stronger immunoreactivity for Aβ3(pE) than for AβN1-42; Aβ3(pE) was also the 
species showing the most consistent age-dependent increase (Lemere et al. 1996). 
Harigaya et al. quantified the contribution of Aβ3(pE) to the total plaque load in AD patients 
to be of up to 25% (Harigaya et al. 2000). Subsequently, also Piccini et al. showed that 
soluble Aβ aggregates found in AD are characterized by a predominance of N-truncated 
variants of Aβ over the full-length protein Aβ1-42; in particular, Aβ3(pE) was the prevailing N-
truncated Aβ species (Piccini et al. 2005). 
In in vitro experiments Schilling et al. have shown that cyclization of glutamate at position 3 
can be driven enzymatically by glutaminyl cyclase (QC) (Fig. 11c) (Schilling et al. 2004). 
The same enzyme has a many-fold increased affinity for the Glutamine residue. In 
addition, it has been shown that QC inhibition significantly reduced Aβ3p(E) formation in 
vitro and in vivo, emphasizing the importance of QC activity during cellular maturation of 




Figure 11 Sequence of Aβ 1–42 and Aβ3(pE). a Aβ 1–42 starts at position 1 with aspartate (D), Aβ3E--42 at position 3 with 
glutamate (E), and Aβ3Q–42 with glutamine (Q). Both N-truncated Aβ3E--42  and Aβ3Q–42 peptides can be converted into 
pyroglutamate- Aβ3(pE). b Schematic drawing of the transgenic vector. TBA2 transgenic mice express Aβ3Q–42 under the 
control of the Thy1 promoter fused to the signal peptide of the pre-prothyrotropin- releasing hormone. c Aβ3(pE) or Aβ3Q 
serves as substrates for generation of Ab3(pE). The conversion of pyroglutamate from N-terminal glutamate (E) is slow, 
in contrast to fast pyroglutamate (pE) formation from glutamine (Q) (Wirths et al. 2009). 
 
 
N-terminal deletions enhance aggregation (Masters et al. 1985; Pike et al. 1995; He et al. 
1999; Schilling et al. 2006) and stability (Kuo et al. 1998) of Aβ peptides in vitro; this 
probably leads as well to an increased toxicity compared to full-length Aβ (Russo et al. 
2002). Russo et al. showed that neuron and astrocyte cultures are affected to a significant 
higher extent by exposition to Aβ3(pE)- 40/42 rather than by the corresponding full-length 
species and that Aβ3(pE) shows a higher resistance to degradation by astrocytes. However, 
other studies reported that the toxicity of Aβ3(pE)-40/42 is similar to that of Aβ1-40 and Aβ1-40 
(Tekirian et al. 1999), and that Aβ3(pE) is not the major variant in AD brain (Lemere et al. 
1996). 
To verify Aβ3(pE)-x toxicity in vivo, this group has recently generated a new transgenic 
mouse model expressing Aβ starting at position 3 with glutamine instead of glutamate and 
ending at position 42 (TBA2 mouse line, Fig 11a,b) to increase the conversion rate to 
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pyroglutamate (Wirths et al. 2009). This model showed for the first time that intraneuronal 
Aβ3(pE)–42 accumulation is sufficient for triggering neuron death and inducing an associated 
neurological phenotype in a transgenic mouse model. The severity of the neurological 
phenotype observed in TBA2 mice, accompanied by Purkinje cell loss and premature 
mortality reflects the in vivo toxicity of Aβ3(pE)-42. Aβ staining in the cerebellum was 
completely restricted to the intraneuronal compartment further supporting the notion that 
intraneuronal pathology is instrumental in neuron loss and that extracellular plaque 
deposition has no drastic effect on cell survival (Fig. 12).  
 
Figure 12 Immunohistochemical staining of TBA2 mouse brain (2-month-old). a Immunostaining with 4G8 revealed 
strong Aβ accumulation in the CA1 pyramidal layer of the hippocampus (inset shows a hippocampus overview at low 
magnification). b Intra- (arrowhead) and extracellular Aβ (asterisk) in the thalamus shown by 4G8 staining. c, d Aβ 
staining (4G8) in the cerebellum is almost completely restricted to the Purkinje cell layer. e, f Most Purkinje cells 
accumulated Aβ3(pE) as shown by an antibody against Aβ3(pE). g GFAP staining of a TBA2 mouse revealed prominent 
Bergmann glia immunoreactivity, whereas wildtype animals (h) were consistently negative. The microglia marker Iba1 
revealed microglia clusters surrounding Purkinje cells and in white matter tracts in TBA2 mice (i), but not in wildtype 
littermates (j). k Immunostaining of Purkinje cells with 4G8 (red) and anti-ubiquitin (green) antibodies showing 
abundant ubiquitin immunoreactivity in 4G8-positive Purkinje cells. l, m Staining of Purkinje cells using antibodies 
against calbindin (green) and 4G8 (inset shows high magnification of a 4G8- and calbindin-positive Purkinje cell). Note 
absent calbindin (asterisk) and extracellular Aβ staining indicating Purkinje cell loss. Only 4G8- positive remnants can 
be seen. Scale bars a, d, e, g–j 100 lm; b, k–m 50 lm; c 500 lm; f inset k, l 20 lm (Wirths et al. 2009).  
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Kuo et al (Kuo et al. 2001) have used an integrated chemical and morphological 
comparison of the Aβ peptides and amyloid plaques present in the brains of APP23 
transgenic mice and human AD patients. The lack of post-translational modifications such 
as terminal degradation, isomerization, racemization, and pyroglutamyl formation of Aβ 
from APP23 mice provides an explanation for the differences in solubility of Aß from 
human AD and transgenic mouse plaques. The same group also demonstrated that in 
another transgenic mouse model (Tg2576), Aβ peptides showed a pronounced N-terminal 
degradation, post-translational modifications, and crosslinkages that were frequently 
observed in the compact Aβ peptide deposits found in AD brain. Thus, under in vivo 
conditions, truncated Aβ molecules appeared to be generated by hydrolysis at multiple 
sites rather than by post-mortem N-terminal degradation (Kalback et al. 2002). 
 
 
1.7.1. RELATED PROJECT: DEVELOPMENT OF A NOVEL MONOCLONAL 
ANTI-Aβ3(pE)-X-ANTIBODY 
 
A striking feature of the APP/PS1KI mouse model is the progressive development of a 
complex pattern of N-truncated Aβ variants that well parallels the composition of Aβ 
species observed in human AD brains. In detail, human Aβ isovariants 2/3-42, 4/5-42, 
8/9/10/11-42, 12/13/14-42 and most notably Aβ3(pE)-x were determined by proteomic 
analysis of brain lysates in a two-dimensional western-blot (Casas et al. 2004). Notably, 
the APP/PS1KI mouse model was the first to show accumulation of Aβ3(pE). 
This group showed recently in the same mice that intraneuronal aggregation of N-terminal 
modified Aβ variants corresponds to robust learning deficits at the age of 6 months, age-
dependent axonopathy, neuron loss in the CA1 region of the hippocampus, synaptic 
deficits, and hippocampus atrophy (Wirths et al. 2007; Wirths et al. 2008; Breyhan et al. 
2009). Recently, a new mouse model has been generated which expresses only N-
truncated Aβ3(pE) in neurons, and demonstrated for the first time that this peptide is 
neurotoxic in vivo inducing neuron loss and an associated neurological phenotype (Wirths 
et al. 2009). 
Given the increasing interest in Aβ3(pE), we have generated two novel monoclonal 
antibodies which we have characterized as highly specific for Aβ3(pE) peptides and herein 
used to analyze plaque deposition in APP/PS1KI mice and compared its pattern with that 
present in brain tissue from sporadic and familial AD cases. 
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1.8. AD BIOMARKERS 
 
The earliest pathological events leading to Alzheimer’s disease (AD) are estimated to 
occur 10–20 years before the appearance of the first cognitive changes in affected 
patients (Price et al. 1999; Yamaguchi et al. 2001). Therefore, identification of biomarkers 
predictive of AD might allow screening for individuals who may benefit from preventive 
therapies like treatment with acetylcholine esterase inhibitors before the development of 
cognitive impairment.  






Recently, Mielke et al. reported in a population-based 70-year-old birth cohort followed for 
18 years that increasing levels of plasma total cholesterol at ages of 70, 75, and 79 are 
related to a reduced risk of dementia between ages 79 and 88 (Mielke et al. 2005). 
However, the association of high levels of plasma cholesterol with a decreased risk of AD 
is in contrast to other reports that suggest high total plasma cholesterol to be a risk factor 
for later dementia (Kuusisto et al. 1997) . 
However, Brain cholesterol is assumed to represent a permanent pool of exclusively 
locally synthesized cholesterol that is protected from exchange with the periphery by its 
inability to cross the blood-brain-barrier (Bjorkhem et al. 2004). The main elimination 
reaction of cholesterol from the brain occurs by its conversion to 24(S)-hydroxycholesterol 
by enzymatic activity of CYP46, which is exclusively expressed in human brain, (Dietschy 
et al. 2001; Lutjohann et al. 2002). It has been shown that 24(S)-hydroxycholesterol in 
contrast to cholesterol is capable of crossing the blood-brain-barrier and therefore can be 
detected in easily accessible body fluids like plasma or serum (Bjorkhem et al. 2001). In 
AD patients the levels of 24(S)-hydroxycholesterol have been shown to be significantly 
elevated in early stages of the disease, potentially due to disruptions in the blood-brain-
barrier. The higher efflux of 24(S)-hydroxycholesterol has been hypothesized to be a result 
of neuron loss or an altered cholesterol metabolism in AD (Locatelli et al. 2002). Therefore, 
elevated 24(S)-hydroxycholesterol plasma levels have been discussed as an easily 
accessible biomarker for the diagnosis of AD in early stages of the disease, but up to now 
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there is no clear evidence for its suitability as an early-onset marker for AD (Schonknecht 
et al. 2002; Teunissen et al. 2003; Irizarry 2004) . 
 
 
1.8.2. CSF BIOMARKERS 
 
Aβ peptide and tau protein are supposed to have a central role in the pathogenesis of AD 
(Hardy et al. 2002). This considered, a large series of studies in blood (Zhang et al. 2004) 
and cerebrospinal fluid (CSF) (Hampel et al. 2004) have been conducted in order to 
evaluate the possibility to use their measurement as a predictive biomarker for the 
diagnosis of AD.  
As a matter of fact, most of these studies report about decreased Aβ1-42 and increased tau 
and phospho-tau in CSF of AD affected patients compared to non-demented persons 
(Blennow et al. 2003; Sunderland et al. 2005); today, measurement of CSF level of these 
peptides is considered a reliable diagnostic procedure with 75–95% sensitivity and 
specificity (Jensen et al. 1999; Blennow 2004; Lewczuk et al. 2004). However, broad 
appliance of CSF scans as a routine test for early AD diagnosis is not possible due to the 
fact that lumbar puncture, especially if repeated over time, represents an invasive 
procedure which is not well tolerated by most of the patients. Contrastingly, blood is an 
easily accessible body fluid and a blood diagnostic test would be highly preferable.  
 
 
1.8.3. BLOOD BIOMARKERS 
 
Unfortunately, studies on plasma Aβ levels have shown contradictory results: while some 
groups reported a correlation between CSF and blood levels of Aβ in HC but not in AD and 
MCI patients (Giedraitis et al. 2007), others found no correlation at all, neither in AD 
patients (Mehta et al. 2001) nor in HC (Mehta et al. 2005).  
However, the fact that around 500 mL of CSF are absorbed into the blood every day let us 
speculate that suitable AD biomarkers can be found also by specific plasma analysis (Hye 
et al. 2006). 
So far, measurement of Aβ levels in plasma yielded highly contrasting results, ranging 
from increased Aβ40 and decreased Aβ42 in AD patients compared to HC (Xu et al. 
2008), no differences (Vanderstichele et al. 2000; Fukumoto et al. 2003) or increased 
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Aβ42 in AD patients (Matsubara et al. 1999). Although the significance of Aβ for 
diagnosing Alzheimer’s disease is controversial, many studies agree on the idea that high 
plasma concentrations of Aβ40 and low plasma concentrations of Aβ42 indicate an 
increased risk of dementia (reviewed in (Kawarabayashi et al. 2008)).  
The different findings in these studies may be due to differences in study designs, 
including variations in age and disease severity of included subjects. A longitudinal study 
showed that plasma Aβ40 and Aβ42 levels measured at the age of 70 years were not 
significantly associated with incident AD (Sundelof et al. 2008). All of the studies, though, 
have shown substantial overlap in plasma Aβ40 and Aβ42 levels between patients and 
controls, thus limiting the diagnostic value of plasma Aβ assessment.  
Plasma Aβ levels are commonly quantified with enzyme-linked immunoabsorbent assays 
(ELISA) using antibodies against a variety of Aβ epitopes (for example (Suzuki et al. 1994; 
Mehta et al. 2000)). Quantification of Aβ in blood is technically difficult and limited by the 
fact that most of it is bound to blood components, including lipids serum albumin, α2-
macroglobulin, immunoglobulins, apolipoprotein J, transthyritin, apoferritin, as well as 
complement components C1q and C3 (Biere et al. 1996; Kuo et al. 2000). 
 
 
1.8.4. IMMUNOLOGICAL BIOMARKERS 
 
Besides the detection of biochemical AD markers, autoimmune responses to molecules 
involved in AD pathology have become a current research focus (Nath et al. 2003; Gruden 
et al. 2004). There seems to be a reduction in the magnitude of lymphocyte stimulation by 
APP in AD patients (Trieb et al. 1996), and anti-Aβ natural antibodies (NAbs) seem to be 
present in sera and CSF of AD patients and HC (Du et al. 2001). However, whether 
autoimmunity plays a direct role in the pathogenesis of AD, or whether NAbs can be used 
as biomarkers for AD, is still open to debate (Singh 1997; McGeer et al. 2001; Tarkowski 







1.8.4.1. RELATED PROJECT: IMMUNE COMPLEXES OF Aβ AND IgM IN 
THE BLOOD OF AD, MCI PATIENTS AND HC 
 
Recently, it has been shown for many forms of cancer that Immune complexes (ICs) of a 
peptide used as biomarker with immunoglobulins of class M (IgM) have better 
performances as a diagnostic tool than the equivalent unbound peptide (Beneduce et al. 
2005; Castaldi et al. 2005; Beneduce et al. 2007). These biomarkers are physiological self-
proteins which are overexpressed in cancer due to the unnatural overgrowth of the cancer 
cells producing them.  
Since AD is also characterized by excessive accumulation of self peptides, in the present 




1.8.4.2. RELATED PROJECT: ANTI- Aβ3(pE)-IgM IN AD  
 
As mentioned above, Aβ3(pE) is suggested to play a crucial role in the development of AD, 
since deposition of it occurs early in AD and Aβ3(pE) exhibited pronounced toxicity in 
neuronal and glial cell cultures (Hosoda et al. 1998; Russo et al. 2002). This is probably 
due to the fact that pyroglutamate modification confers proteolytic resistance (Saido 1998; 
Russo et al. 2002) and an initial rate of aggregation up to 250-fold higher when compared 
to normal Aβ (He et al. 1999; Schilling et al. 2006). The drastically increased proteolytic 
stability of Aβ3(pE) might also be the reason for the correlation of the Aβ3(pE) content with 
severity of the sporadic AD, as suggested in a previous study (Guntert et al. 2006). In vitro 
studies showed that Aβ3(pE) probably serves as a nidus for and promoter of aggregation of 
full length Aβ (Schilling et al. 2006). 
Therefore, it can be hypothesized that the prevention of Aβ3(pE) formation might represent 
a new strategy for the causal treatment of AD as well as other pyroglutamate-related 
amyloidosis; it is consistent with this idea that a higher natural immunoreactivity specific for 
Aβ3(pE) also participate in delaying the onset of the disease. In fact, reduction or inhibition 
of accumulation of Aβ3(pE) could, in turn, prevent Aβ aggregation by clearance of a major 
nucleation factor and enhance neuronal survival.  
In this study, a new assay aimed to measure the level of NAbs against N-terminus of 
Aβ3(pE) as well as other specific Aβ epitopes has been developed. The purpose was to 
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investigate whether and which natural IgM immunoglobulins are present in the blood of AD 
patients, MCI individuals and HC, and to search for possible differences between groups. 
In details, the levels of anti-Aβ-, anti-Aβx-42-, anti-Aβx-40-, and anti-N-terminus of Aβ3(pE)-
IgMs have been measured. The findings may also point to the role that NAbs play in the 
pathogenesis of the disease. 
 
 
1.9 Focus of the present work 
 
Aim 1: Expression analysis of proteins in APP/PS1KI mice 
The first part deals with the Western blot characterization of whole brain and synaptosomal 
fractions of APP/PS1KI mice in order to support data from mRNA studies and 
electrophysiological recordings showing synaptic deficits  and inflammation processes 
developing between 2 and 6 months of age, corresponding to the time span when 
cognitive impairment and neuron loss have been shown to establish. 
 
Aim 2: Characterization of novel monoclonal anti-pyroglutamate Abeta antibodies. 
The second part deals with the characterization of 2 monoclonal antibodies directed 
against Aβ3(pE)-x generated by Synaptic Systems and the validation by dot blot, ELISA and 
immunohistochemistry. 
 
Aim 3: Establishing of an ELISA test for Abeta-IgM immune complexes and 
validation in human plasma samples 
The third part deals with the validation and measurement of the presence of immune 
complexes of Aβ and IgM in the plasma of AD and MCI patients and HC to evaluate 
whether the level of such immune complexes is correlated with the disease state of the 
individual. In order to perform these measurement a novel ELISA test has been 
developed. 
 
Aim: 4 Establishing of an ELISA test for autoantibodies against pyroglutamate 
Abeta-IgM and validation in human plasma samples 
The fourth part deals with development of a novel ELISA test for the measurement of anti- 
Aβ3(pE)-x-IgM autoantibodies in the human plasma. The presence of the autoantibodies has 
been validated by HPLC purification and western blot. The test was validated using 30 AD, 
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15 MCI and 30 HC plasma samples to evaluate differences in the mean level of 
















2.1 STATISTICAL ANALYSIS 
 
For synaptic and inflammatory markers, and for blood biomarkers, differences between 
groups were tested with either one-way analysis of variance (ANOVA) followed by post-
hoc Bonferroni's multiple comparison tests, paired t-test for pair-wise comparisons or 
unpaired t-tests as indicated in the figure legends. All data were given as means ± 
standard deviation. The diagnostic powers were determined by ROC curve analysis. Chi-
square test on independence was used to analyze, if the gender distribution was 
significantly different between the three groups and if there is a difference between the two 
patient groups in relation to the number of family members with dementia. All tests were 
two-tailed. 
Significance levels were given as follows: ***P < 0.001; **P < 0.01; *P < 0.05. All 
calculations were performed using GraphPad Prism version 4.03 for Windows (GraphPad 
Software, San Diego, CA, USA). 
 
 
2.2 APP/PS1KI MICE 
 
The generation of APP/PS1KI mice has been described in details in Casas et al. 2004 
(Casas et al. 2004). In brief, human mutant APP751, harbouring the Swedish and London 
mutations (APP751SL) is expressed under the control of the murine Thy-1 promoter, 
whereas murine PS1 with two FAD-linked mutations (PS1 M233T and PS1 L235P) is 
expressed under the control of the endogenous mouse PS1 promoter (“knock-in”). All mice 
named as PS1KI were homozygous for PS1 knock-in mutations; the APP/PS1ki mice 
harboured one additional hemizygous APP751SL transgene. All animals were handled 
according to German guidelines for animal care. All mice were kept on standard mouse 
diet and all experiments were carried out according to German animal protection 
guidelines. In total 6 APP/PS1KI and 6 PS1KI mice have been used in the current study 







2.3 TBA2 MICE 
 
The generation of TBA2 mice has been described in Wirths et al 2009 (Wirths et al. 2009). 
These mice have been generated by inserting the cDNA of a murine thyrotropin-releasing 
hormone-Aβ fusion protein mTRH-Aβ3Q–42 into the vector pUC18 containing the murine 
Thy-1 sequence applying standard molecular biology techniques and verified by 
sequencing. The transgenic mice were generated by male pronuclear injection of fertilized 
C57Bl/6J oocytes (PNI, generated by genOway, Lyon, France). The resulting offspring 
were further characterized for transgene integration by PCR analysis and after crossing to 
C57Bl/6J wildtype mice for transgene expression by RT-PCR. The line with the highest 
transgene mRNA expression was selected for further breeding (named TBA2).  
 
 
2.4 PROTEIN EXTRACTION FROM MOUSE BRAIN 
 
For western blot, mouse brain hemispheres were homogenized in 10 volumes of lysis 
buffer (0.32M Sucrose, 5mM HEPES, pH 7.5) including complete protease inhibitor 
cocktail (Roche), and centrifuged at 12,000g for 20 minutes at 4 °C. The supernatants 
were immediately frozen and stored at -80 °C until further analysis. 
 
For synaptosome enrichment, brain hemispheres were homogenized in 10 volumes of 
0.32 M sucrose, 5 mM HEPES, pH 7.5 including complete protease inhibitor (Roche) using 
a glass-teflon homogenizer. Homogenates were centrifuged at 10,000g for 10 min and the 
supernatant was centrifuged at 12,000g for additional 20 min. The resulting pellet contains 
the crude synaptosomal fraction.  
 
 
2.5 PHOTOMETRIC MEASUREMENT OF PROTEIN CONCENTRATION 
 
Protein concentration was measured by use of the commercially available Roti-Quant 
universal solution (Carl Roth GmbH, Karlsruhe, Germany), based on the biuret reaction. 
Absorbance was measured by use of a photometer at 595 nm. Concentrations of proteins 
were calculated by comparison with a calibration curve derived from BSA samples with a 
range in concentration from 0 – 20 mg/mL. All samples were measured in a transparent 
 52
96-well culture plate. In each well 2 µL of sample were diluted with 200 µL of detection 
solution Roti-Quant universal and incubated for 30 min at 37 °C before measurement. 
 
 
2.6 WESTERN BLOT 
 
For inflammatory and synaptic markers, and Aβ, brain homogenates containing equal 
amount of proteins were used for SDS-PAGE electrophoresis. For IC and IgM localization, 
fractions corresponding to 280 nm absorbance peaks after HPLC purification were tested. 
Electrophoresis was performed using 4–12% sodium dodecylsulfate–polyacrylamide gels 
(Vario-Gel, Anamed, Germany). Proteins were transferred to nitrocellulose membranes 
(Hybond-ECL, Amersham Biosciences, USA) by semi-dry blotting and then blocked in 
10% non-fat dry milk in TBS containing 0.05% Tween (TBS-T) for 1 h at room 
temperature. For Aβ detection, the membrane was heated in PBS in a microwave for 5 
minutes right after transfer. Blots were then incubated with the primary antibody directed 
against the protein of interest overnight at 4 °C followed by secondary peroxidase-
conjugated antibodies for 2 h at room temperature, or alternatively, with peroxidase- 
conjugated goat anti-human-IgM (Sigma-Aldrich) at 1:1,000 in TBS-T for 2 h. Protein 
bands were revealed using chemiluminescence solution and peroxide hydrogen as 
substrates on a Curix60 developing machine (Agfa-Gevaert N.V., Mortsel, Belgium).  
Quantification was done by densitometry of Western blot bands using ImageJ software 
(NIH, http://rsb.info.nih.gov/ij). A mouse monoclonal antibody against Tubulin (Chemicon, 




2.7 GENERATION OF MONOCLONAL ANTI-Aβ3(pE) ANTIBODIES  
 
The first phases of the antibodies development have been carried out at Synaptic System 
(Goettingen, Germany). Briefly: 
 
Phase I / Immunization:  
3 balb/c mice were immunized with 90 to 150 µg of a KLH coupled pyroglutamate-Aβ-
peptide with the sequence pEFRHD-C. Animals are immunized over a period of 17 days 
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every second day and one day before fusion. As immune stimulating agent incomplete 
Freund's adjuvant combined with CpG oligo-nucleotides has been used.  
 
Phase II / Fusion:  
After immunization cells from knee lymph knots and spleen of all three animals are 
prepared and fused with the P3-X63-Ag8 myeloma cell line in the presence of PEG 1500. 
After fusion cells are plated on 24-well plates resulting in 360 oligo clones each consisting 
of 5-10 clones. Cells are cultivated for 10 days in selective and conditioned medium 
selecting for fused cells only.  
 
Phase III / Screening and subcloning:  
All 360 oligo clone supernatants are screened by 3 different ELISA using as capture 
molecules Aβ3(pE)-7, Aβ1-7 and Fetal calb serum (FCS). The clones showing the highest 
Aβ3(pE)-7/ Aβ1-7 and Aβ3(pE)-7/FCS signals ratio were selected and further analyzed. 
 
 
2.8 DOT BLOT 
 
1 μL of each studied Aβ peptides (see Table 2) was spotted on a nitrocellulose membrane 
in serial dilutions with a starting concentration of 50ug/mL in PBS and air dried. The 
membrane has been blocked with 10% non-fat dry milk in TBS-T for 1 h at 4°C. The blot 
was then incubated overnight at 4°C with the selected supernatant diluted 1:25 in TBS-T 
5% non-fat dry milk. After 1 h incubation at room temperature with a peroxidase 














2.9 IMMUNOHISTOCHEMISTRY ON PARAFFIN SECTIONS 
 
Mice were anaesthetized and transcardially perfused with ice-cold phosphate-buffered 
saline (PBS) followed by 4% paraformaldehyde. Brain samples were carefully dissected 
and postfixed in 4% phosphate-buffered formalin at 4 °C.  
Human brain samples from frontal cortex were obtained from the Netherlands Brain Bank 
(NBB), Amsterdam, Holland. 
Immunohistochemistry was performed on 4 µm paraffin sections according to the protocol 
showed below. Supernatants from oligoclones cultures were used as primary antibodies in 
1:10, 1:100 and 1:1000 dilution in PBS with 10% FCS (fetal calf serum) and detected with 
biotinylated secondary anti-mouse-IgG antibodies (Dako Denmark A/S, Glostrup, 
Denmark). 
 
1. Deparaffinize:  
a. 2x5 min xylol  
b. 10 min 100% ethanol 
c. 5 min 95% ethanol 
d. 1 min 70% ethanol 
e. 1 min distilled water 
2. Peroxidase Block  
a. 30 min in 200 mL PBS with 2 mL 30% H2O2 
3. microwave treatment  
a. 10 min in 0.01M citrate buffer pH 6.0 (citric acid monohydrate) 
b. 15 minutes cool down 
4. wash 1min in distilled water. 
5. wash 15 min PBS + 0,1% Triton-X100 
6. wash 1 min with PBS 
7. formic acid treatment 
a. 3 min incubation in 88% formic acid 
b. 2x 1 min wash in PBS  
8. unspecific block for 1 h in PBS +10% FCS (fetal calf serum) +4% dry milk 
(40mg/ml) 
9. Discard blocking solution  
10. overnight incubation with primary antibody in PBS+10% FCS room temperature 
 55
11. wash 15 min with PBS+ 0,1% Triton-X100 
12. 1 h incubation with secondary antibody 1:200 in PBS including 10% FCS for 1 h at 
37 °C 
13. wash 15 min with PBS 
14. 1,5 h incubation with ABC-Vectastain-Complex solution (1:100 solution A + 1:100 
Solution B in PBS +10% FCS) at 37 °C 
15. wash 15 min with PBS 
16. stain with DAB (3,3-diaminobenzidine-tetrahydrochloride, Sigma) 25 mg/mL in 50 
mM Tris/HCl pH 7.5 
17. wash in PBS 
18. Hematoxylin staining 
a. 40 seconds in Hematoxylin (Mayers hemalaun solution) 
b. 5 min tap water 
19. ascending ethanol-series,  
a. 1 min 70% ethanol 
b. 5 min 95% ethanol 
c. 10 min 100% ethanol 
d. 2x10 min Xylol 
20. 7. embedding with a quick hardening mounting medium 
 
 
2.10 PATIENTS AND SAMPLES 
 
Plasma samples (stored at -70 °C) from 30 out-patients with mild to moderate AD, 15 
patients with mild cognitive impairment (MCI) and 30 healthy controls (HC) were analyzed. 
The patients were recruited at the Memory Clinic at the Department of Geriatrics, Uppsala 
University Hospital. All AD patients were diagnosed according to DSM IV (association 
2000) and NINCDSADRDA (McKhann, Drachman et al. 1984). The MCI patients met the 
Petersen criteria (Winblad, Palmer et al. 2004) for MCI. All plasma samples were a 








Plasma samples from 5 AD patients and 5 HC showing high reactivity to Aβ-IgM immune 
complexes or anti-Aβ autoantibodies in a preliminary assay were grouped and analyzed by 
gel filtration HPLC. Five hundred microliters of pooled samples were analyzed using a gel-
filtration column Superdex 200 10/300 GL (GE Healthcare, Freiburg, Germany) on an 
ACTA Basic system (GE Healthcare, Freiburg, Germany). The elution was carried out in 
PBS at a flow rate of 1 ml per minute, and sample absorbance was monitored at 280 nm. 
Fractions were collected every 30 seconds, immunoreactivity was tested by ELISA and the 
fractions corresponding to the highest immunoreactivity were pooled and used as 
reference standard. Before running the samples, a calibration run was carried out 
according to the manufacturer’s instructions. 
 
 
2.12 ELISA ASSAYS 
 
Three different ELISA assay were newly designed for the detection of Aβ, Aβ-IgM immune 
complexes (IC) and anti-Aβ autoantibodies. 
 
 
2.12.1 Aβ ELISA 
 
The Aβ level in gel-filtration fractions was determined as follows: 96-well ELISA plates 
were coated with 50 µL per well of 1 µg/mL of mouse anti-human Aβ antibody directed 
against residues 17-24 (4G8, Signet Laboratories, Dedham, MA, USA) in PBS at 4 °C 
overnight and then blocked for 2 h with 3% BSA in PBS at 37 °C. After blocking, 50 µL of 
gel-filtration fractions in PBS containing 1% BSA and 0.05% Tween 20 (PBS-B-T) were 
incubated for 1.5 h at 37 °C. The wells were then washed with PBS containing 0.05% 
Tween 20 and incubated with 50 µL of rabbit polyclonal anti-Aβ 692 (generous gift from 
Gerd Multhaup, Free University of Berlin) at a 1:1,000 dilution in PBS-B-T for 1.5 h at 37 
°C. Aβ was revealed using peroxidase-conjugated goat anti-rabbit-IgG (Dako, Glostrup, 
Denmark) in a 1:1,000 dilution in PBS-B-T and developed with TMB (Pierce 
manufacturing, Appleton, IL, USA) and hydrogen peroxide as substrate. The results of Aβ 
determination in the gel-filtration fractions were reported in optical density. 
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2.12.2 Aβ–IgM IC ELISA 
 
96-well ELISA plates were coated with 50 µL per well of 1 µg/mL of 4G8 antibody (Signet 
Laboratories, Dedham, MA, USA) in PBS at 4 °C overnight and then blocked for 2 h with 
3% BSA in PBS. After blocking, 50 µL of serially diluted reference standard or samples in 
PBS-B-T were incubated for 1.5 h at 37 °C. The Aβ–IgM complex was revealed using 
peroxidase-conjugated anti-human-IgM (Sigma-Aldrich, Munich, Germany) in PBS-B-T 
and developed with TMB and hydrogen peroxide as the substrate. Aβ–IgM IC levels in the 
plasma were expressed in arbitrary units/mL (AU/mL) by using gelfiltration-purified Aβ–IgM 
reference standards to design a calibration curve, where the undiluted standard was 
assigned 1,000 AU/ml; concentration was determined by interpolation of samples 
absorbance on the calibration curve. The linear range of the assay was between 3.9 and 
62.5 AU/ml. The samples with values above 62.5 AU/ml were further diluted and re-
measured. The assay was standardized and its analytical performance evaluated: inter- 
and intra-assay coefficient of variation (CV) was less than 10%. Aβ–IgM cut-off was 
selected as the best combination of specificity and sensitivity according to the receiver-
operating characteristic (ROC) curve. 
 
 
2.12.3 ANTI-Aβ-IgM ELISA 
 
96-well ELISA plates were coated with 50 µL per well of the following antigens: 1 µg/mL of 
a synthetic fragment of human Aβ starting at position 3 with a modified pyroglutamate and 
ending at position 7 (pEFRHD); 1 µg/mL of synthetic full length human Aβ 1-42 
(DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA); 0.1 µg/mL of synthetic 
human Aβ38-42 (N-GVVIA); 0.1 µg/mL of synthetic human Aβ37-40 (N-GGVV) (all 
peptides from Synaptic Systems GmbH, Goettingen, Germany) in PBS at 4°C overnight 
and then blocked for 2 hours with 3% BSA in PBS. After blocking, 50 µL of fractions, 
serially diluted reference standards or samples in PBS-B-T were incubated for 1.5 h at 
37°C. The IgM autoantibodies were revealed using peroxidase-conjugated anti-human-IgM 
(Sigma, Saint Louis, MI, USA) in PBS-B-T and developed with TMB (Pierce 
manufacturing, Appleton, IL, USA) and Hydrogen peroxide as the substrate. The amount 
of IgM in the plasma was expressed in arbitrary units/mL (AU/mL) by using Gel-filtration 
purified Aβ-IgM reference standards to design a calibration curve; concentration was 
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determined by interpolation of samples absorbance on the calibration curve. The samples 
with values above 32 AU/mL (matching the upper limit of the calibration curve) were 
further diluted and re-measured. The assay was standardized and its analytical 
performance evaluated: coefficient of variation (CV) inter- and intra-assay was less than 
10%. Range of linearity of the assay was between 0.9 and 32 AU/mL. 
 
 
2.13 ANTIBODIES USED IN THE PROJECT 
 
ANTIBODY SOURCE MANUFACTURER WORKING DILUTION 
Primary antibodies    
PSD95 Rabbit Cell Signalling Technology, Inc, Danvers, MA, USA 1:1000  
Clathrin light chain Mouse Synaptic System, Goettingen, Germany 1:2000 
SNAP25 rabbit Sigma, Saint Louis, MI, USA 1:5000 
GFAP mouse Chemicon International, Temecula, California, USA 1:3000 
WO-2 (human Aβ5-8) mouse 




4G8 (human Aβ17-24) mouse Signet Laboratories, Dedham, MA, USA 1:1000 
692  rabbit Generous gift from Prof. Gerd Multhaup, FU Berlin 1:2000 
β-Actin mouse Sigma, Saint Louis, MI, USA 1:2000 
tubulin rabbit Chemicon International, Temecula, California, USA 1:3000 
HRP-conjugated Secondary antibodies 
Anti-mouse-IgG goat Dako, Glostrup, Denmark 1:1000 
Anti-rabbit-IgG Swine Dako, Glostrup, Denmark WB 1:3000 ELISA 1:5000 
Anti-human-IgM goat Sigma, Saint Louis, MI, USA 
IC ELISA 1:3000 
Anti-Aβ-IgM ELISA 
1:20000 
Biotinylated secondary antibodies 
Anti-mouse-IgG rabbit Dako, Glostrup, Denmark 1:200 




















2 and 6 months-old APP/PS1KI and PS1KI mice were tested by western blot to measure 
the level of GFAP expression in the brain. Western blotting verified the up-regulation of 
GFAP in 2- (P < 0.01) and 6-month-old APP/PS1KI mice (P < 0.05) on the protein level 
(Fig. 12) compared to PS1KI mice. This result was corroborated by immunohistochemical 
staining against GFAP and S100A6, showing strong astrogliosis in the hippocampus of 6-
month-old APP/PS1KI mice, whereas age-matched PS1KI were almost devoid of any 
astroglial reaction (Wirths et al. 2008).  
 
 
Figure 13 A Protein levels of GFAP are significantly increased in both 2- and 6-month-old APP/PS1KI mice,as shown 




2 and 6 months old APP/PS1KI and PS1KI brains were homogenized and synaptosome-
enriched fractions (P2) separated from the whole-brain fractions (S2). Western blot 
analysis confirmed the enrichment of P2 fractions with synaptic specific marker PSD95, 
while tubulin was enriched in the S2 fraction, as expected (Fig. 13). Interestingly, western 
blot analyses evidenced a high enrichment of Aβ in the synaptosome fraction, the 
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enrichment being more marked in 6 months-old mice, while APP level was constant for P2 
and S2 fractions for both the considered time points. These finding clearly indicate a 
strong association of Aβ with the synaptic area. 
 
 
Figure 14 Western blot of P2 and S2 fractions of 2 and 6 months old APP/PS1KI mice for synaptosome marker PSD95, 
Tubulin, APP and Aβ. The image confirms the purification of the synaptosome fraction, and an enrichment of Aβ in it. 
 
 
The levels of pre- and post-synaptic proteins were quantified by Western blot in whole 
brain extracts and synaptosome enriched fractions of 2 and 6 month-old mice. The 
proteins analyzed were: Synaptosome-associated protein of 25 kDa (SNAP25), a highly 
conserved protein anchored to the cytosolic face of membranes required for exocytosis of 
presynaptic vesicles; neuron-specific Clathrin light chains, which is enriched in synaptic 
nerve terminals participating in presynaptic vesicle endocytosis; PSD-95, a major protein 
at the postsynaptic density which has an important function in regulating the surface 
expression of glutamate receptors, thereby representing a critical factor regulating synaptic 
plasticity.  
At 2 months, there was no difference between APP/PS1KI and PS1KI control mice. In 
whole brain Western blots only PSD-95 levels were significantly reduced at the age of 6 
months in APP/PS1KI mice (Fig. 14). Of interest, the levels of all three markers were 







Figure 15 Western blot analysis of pre- (clathrin light chain; SNAP25) and post-synaptic markers (PSD-95). A While 
in whole brain lysates, only the levels of PSD-95 declined significantly, B the levels of all synaptic markers were 
decreased in synaptosome enriched fractions in 6-month-old APP/PS1KI mice. At 2 months, there was no difference 
between APP/PS1KI and PS1KI control mice. Values are given as mean values ± SEM, ***P\0.001; **P\0.01, *P\0.05. 
Figure from (Breyhan et al. 2009). 
 
3.2 DEVELOPMENT OF NOVEL MONOCLONAL ANTI-Aβ3(pE)-
ANTIBODIES 
 
After hybridoma cells have been created from both long- and short-term immunization 
protocols, they are plated to obtain oligoclones each consisting of 5-10 clones. By 
screening each oligoclone’s supernatant by ELISA those showing highest ratio of reactivity 
against Aβ3(pE)-7 over reactivity against Aβ3-7 and the FCS blank control have been 
selected and further characterized for their specificity and affinity by IHC analysis (Tab. 4 
and 5). 










7 1,689 0,360 0,175 1, 2a, M 
48 1,170 0,339 0,339 2a, M 
50 0,888 0,214 0,090 2b, M 
72 1,199 0,389 0.090 1, 2a, M 
101 1,507 0,322 0,121 2a, 3, M 
157 2,205 0,398 0,297 2b, M 
192 1,327 0,246 0,123 2a 
223 1,164 0,386 0,303 1, 2b, M 
234 0,750 0,219 0,176 2a, M 
239 1,200 0,339 0,106 1, 2a, M 
245 2,206 0,283 0.093 M 
248 1,596 0,365 0,040 1, 2a, 3, M 
314 2,008 0,221 0,185 2a, M 
357 1,771 0,255 0,144 2a, M 
Table 3 ELISA of first oligoclones series from long-term immunization protocol. The selected oligoclones are 
evidenced in grey (courtesy of Synaptic System GmbH, Goettingen) 
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70 1,2 0,09 0,1 1/2a/2b 
73 0,13  0,03 1 
93 1,4 0,15 0,24 1/2b/M 
44 1,9 0,05 0,04 2b/M 
106 1,6 0,05 0,05 2a/M 
117 1,3 0,06 0,12 1/2a/M 
141 2,0 0,17 0,11 2a/M 
165 1,2 0,18 0,07 1/2a/M 
121 1,4 0,15 0,1 1/2a/M 
136 2,0 0,15 0,12 M 
Table 4 ELISA of first oligoclones series from short-term immunization protocol. The selected oligoclones are 
evidenced in grey (courtesy of Synaptic System GmbH, Goettingen) 
 
Supernatants from oligoclones 72, 157, 192, 245, 248 and 357 of the long-term 
immunization set, and from oligoclones 70 106 141 and 136 of the short-term 
immunization set were used to stain by IHC brain sections from APP/PS1KI and TBA2 
mice and evaluate their capacity to stain Aβ3(pE)-positive plaques (Tab. 6). 
 




72 + Purkinje cells   
157 +++ Purkinje cells, 




intracellular in CA1 
/ background 
1:10 / background 
1:100 +++ 
1:1000 +++ 
192 +++ Pyramidal cells 
1:100 no staining 
Plaques and 
intracellular in CA1 




245 + Purkinje cells   
248 +++ 1:1000  Plaques and 
intracellular in CA1 




357 ++ Pyramidal cells   
70 (+)   
106 (+)   
141 +++ Purkinjecells, 
negative in CA1 





136 Astrocytes Astrocytes  
Table 5 IHC on brain slices of transgenic AD mouse models stained with oligoclones of anti-Aβ3(pE) monoclonal 
antibodies. Grey-highlighted samples are those showing intense specific staining for Aβ plaques and low background. 
The arbitrary intensity of the staining is indicated with 0 to 3 + crosses. 
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Dot Blot analysis 
Supernatants from oligoclones 72, 157, 192, 245, 248, 357 and 141 showed good affinity 
for Aβ plaques and very low unspecific background and have therefore been selected for 
further analysis. Their specificity for the pyroglutamate modification and their sensitivity 
threshold have been evaluated with a dot blot experiment against N-terminal fragment and 
full-length Aβ3p(E)-42, full-length Aβ1-42 and N-truncated native Aβ3-7 (Tab. 7). 
 
Clone-Nr. Aβ3(pE)-7 Aβ3-7 Aβ3(pE)-42 Aβ1-42 
72 5 ng negative 0,5 ng negative 
141 5 ng Negative 50 ng negative 
157 5 ng Negative 50 ng negative 
192 5 ng Negative 5 ng negative 
245 0,5 ng Negative 0,5 ng negative 
248 5 ng Negative 5 ng negative 
357 0,5 ng Negative 0,5 ng negative 
Table 6 Dot blot against 4 Aβ-derived peptides of selected anti-Aβ3p(E) oligoclones. All samples showed no cross-
reaction with unmodified peptides, and a sensitivity threshold of at least 50 ng 
 
 
Immunohistochemistry on AD brain  
Brain slices obtained from post mortem AD patients at braak stage 4 are stained with the 
selected supernatants to verify the recognition of Aβ plaques in human (Tab. 8). 
 
Clone-Nr. 1:10 1:100 
72 - - 
141 +++ some 
background 
+++ 
157 +++ +++ 
192 + 1:10 ++ 1:10 
245 - - 
248 + 1:10 ++ 1:10 
357 + + 
Table 7 IHC on post-mortem brain slides from AD patients 
 
1ST SUBCLONING 
Selected oligoclones have been subcloned in order to obtain purer composition of 
supernatant in terms of Immunoglobulin classes. Of the 7 clones selected, clones 141, 
157, 248 and 357 produced new colonies. The subclones have been tested in IHC 
experiments on mouse brain to assess whether there had been improvement in specificity 





141 APP/PS1KI serial dilutions  157 APP/PS1KI serial dilutions 









C6 1:10 +++ some background 
1:100 +++ 
1:1000 +++ 
 B9 1:10 +++ 
1:100 +++ 
1:1000 +++ 
E2 1:10 +++ some background 
1:100 +++ some background 
1:1000 +++ 
 B10 1:10 +++ 
1:100 ++ 
1:1000 ++ 
F8 1:10 +++ 
1:100 ++ 
1:1000 - 
 C3 1:10 ++ 
1:100 ++ 
1:1000 + 
G3 1:10 ++++ some background 
1:100 +++ 
1:1000 +++ 
 C9 1:10 +++ 
1:100 +++ 
1:1000 ++ 
H5 1:10 +++ some background 
1:100 +++ 
1:1000 ++ 
 C12 1:10 +++ 
1:100 +++ 
1:1000 +++ 
   D1 1:10 +++ 
1:100 +++ 
1:1000 +++ 
   
248 APP/PS1KI serial dilutions  357 APP/PS1KI serial dilutions 
B5 1:10 +++ 
1:100 +++ 
1:1000 +++ 
 G7 1:10 + 
1:100 + 
1:1000 - 
C2 1:10 +++ 
1:100 +++ 
1:1000 +++ 
 H1 1:10 + 
1:100 + 
1:1000 - 








E2 1:10 +++ 
1:100 +++ 
1:1000 +++ 
 H4 1:10 + 
1:100 - 
1:1000 - 
F2 1:10 ++++ 
1:100 +++ 
1:1000 +++ 
 H6 1:10 + 
1:100 + 
1:1000 - 
G6 1:10 +++ 
1:100 ++ 
1:1000 - 
 H7 1:10 + 
1:100 + 
1:1000 - 
Table 8 IHC on slides from APP/PS1KI mice with the supernatant obtained from the first subclones. Each supernatant 
has been tested in 3 dilutions (1:10, 1:100, 1:1000) and the intensity of the signal evaluated visually assigning a score 









Colonies producing the supernatants displaying the best staining properties have been 
further subcloned to obtain monoclonal colonies. The supernatants obtained have been 
used in an IHC experiment (Tab. 10) to determine the 2 clones having the highest 
sensitivity and specificity characteristics. 
 
141H5 APP/PS1KI serial dilutions  157B10 APP/PS1KI serial dilutions 
C5 1:100 - 
1:1000 - 
 C2 1:100 +++ 
1:1000 +++ 
E4 1:100 + 
1:1000 - 
 C4 1:100 + 
1:1000 + 
E8 1:100 - 
1:1000 - 
 D2 1:100 ++ 
1:1000 - 
F1 1:100 + 
1:1000 - 
 E1 1:100 + 
1:1000 - 
H1 1:100 - 
1:1000 - 
 F6 1:100 ++ 
1:1000 - 
   H9 1:100 +++ 
1:1000 +++ 
   
248 B5 APP/PS1KI serial dilutions 
A11 1:100 + 
1:1000 - 
B1 1:100 +++ 
1:1000 +++ 






F1 1:100 - 
1:1000 - 
G4 1:100 + 
1:1000 - 
H1 1:100 +++ 
1:1000 +++ 
Table 9 IHC on brain slices from APP/PS1KI mice with supernatants from second subcloning to determine the 2 clones 
having the highest sensitivity and specificity characteristics. 
 
 
Supernatants 248b5b1 (re-named 2-48, subclass IgG1) and 157b10H9 (re-named 1-57, 
subclass IgG2b) have finally been selected as showing the best results for staining of 
Aβ3p(E)-positive plaques. Figures 16, 17 and 18 show the comparison of sensitivity and 




Figure 16 Immunohistochemical staining of brain 
sections from APP/PS1KI mice (A, C, E) and AD 
patients (B, D, F) with successive subclones of the 2-48 
antibody: 248 (A, B), 248B2 (C, D), and the definitive 
248B2B1 (E, F) 
 
Figure 17 Immunohistochemical staining of brain 
sections from APP/PS1KI mice (A, C, E) and AD 
patients (B, D, F) with successive subclones of the 1-57 






Figure 18 Comparison of Dot Blot performance for the newly developed 1-57 and 2-48 monoclonal antibodies and 3 
commercially available antibodies. The peptides used for recognition are Aβ1-42, Aβ1-4, Aβ3-7, Aβ3(pE)-7 and Aβ3(pE)-42. 
AβPyrGlu is a commercially available monoclonal antibody recognizing specifically Aβ starting at position 3 with a 
pyroglutamate, Aβ(N) recognize only Aβ starting at position 1 and WO-2 is directed against residues 4 to 10 
 
 
3.3 IMMUNE COMPLEXES OF Aβ AND IgM IN THE BLOOD OF AD, MCI 
PATIENTS AND HC 
 
There were no significant age differences between AD patients, MCI patients and HC (F = 
0.3, df = 2, 72; P = 0.74). Patients with MCI diagnosis were not significantly older at onset 
of the disease than AD patients (F = 2.3, df = 1, 42; P = 0.13). As expected, the mean 
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MMSE score was higher in MCI compared to AD patients (F = 44.3, df = 1, 40; P\0.0005). 
Gender distribution was not significantly different between the three groups (Chi2 = 1.2, df 
= 2; P = 0.55) and the proportion of family members with dementia did not differ 
significantly between the two patients groups (Chi2 = 0.8, df = 1; P = 0.38) (Table 11).  
 
 
Table 10 Demographic data of the studied groups. 
 
 
In order to identify circulating Aβ–IgM complexes, plasma samples from ten individuals 
were pooled and analyzed by gel filtration. Fractions collected from the column were 
tested for the presence of generic Aβ and Aβ–IgM complexes using dedicated ELISA 
assays (Fig. 19A). A strong immunoreactivity against Aβ was observed in the fraction 
eluting at high molecular weight (>500 kDa) (Fig. 19A).  
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Figure 19 (A) Gel-filtration HPLC of pooled plasma samples. Proteins are separated according to their molecular 
weight, with the larger proteins eluting first. Total protein concentration of each fraction was measured at 280 nm (gray 
line). The characteristic peaks were as follows: empty volume with a MW[500 kDa (IgMs), IgGs with a MW of *150 
kDa, and the albumin peak at *66 kDa. A direct ELISA performed on each fraction to measure the quantity of generic 
Aβ (diamonds) shows that most of Aβ elutes in the empty volume and IgG fractions suggesting that Aβ(Kuo et al. 
2000) in the blood is strongly associated with antibodies. (B) Western blot against Aβ in the empty volume (IgM) 
fraction and IgM showing the presence of Aβ in the IgM fraction. 
 
 
In the same fraction high reactivity for complexes of Aβ and IgM was also found, thus 
providing the first evidence of the occurrence of circulating Aβ–IgM immunecomplexes 
(Fig. 20C). Reactivity for generic Aβ was also found in the fractions eluting at 150 kDa (IgG 
fraction) and at low molecular weight (Fig. 19A), confirming previous observations (Kuo et 
al. 2000). The high molecular weights fraction contained components migrating at the 
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expected molecular weight for reduced IgM that were stained by antihuman-IgM antibodies 
(Fig. 19B).  
 
 
Figure 20 A Sandwich ELISA. 96-well titer plates are coated with anti-Aβ (4G8). After incubation with plasma 
samples, the wells are washed and incubated with an anti-IgM heavy chain antibody conjugated with HRP. Signal of 
bound molecules is therefore only produced by complexes of both IgM and antigen. B Calibration curve obtained by 
serial dilutions of the IgM fraction. C Aβ-IgM (diamonds) immune complexes in the fractions derived from gel-
filtration HPLC compared to total protein concentration (solid line). 
 
 
To assess the relevance of these findings, plasma samples from 75 patients with AD, MCI, 
and from healthy donors were analyzed for the presence of Aβ–IgM ICs. Serial dilutions of 
the gel filtration-purified IC fraction have been used to draw a reference calibration curve. 
By interpolation with the standard curve, Aβ–IgM IC concentration in the plasma samples 
has been expressed in arbitrary units (AU)/ml. According to ANOVA test, no significant 
differences among the three diagnostic groups were observed (Student t test P value AD 
vs. HC = 0.18, AD vs. MCI = 0.61, MCI vs. HC = 0.10) (Fig. 21). ROC curve analysis 
showed that specificity was only 46.67% when sensitivity was set at 80%, and by setting 





Figure 21 Analysis of Aβ–IgM 
immune complexes. a Levels of 
Aβ–IgM immune complexes in 
the different diagnostic groups. b 
The comparison of the mean 
values do not show any 
significant difference. c ROC 
curve analysis shows a certain 
difference in the distribution of 
the immune complexes plasma 
concentration between AD and 
HC groups, which however was 






Table 11 Comparison of specificity, sensitivity, positive predictive value (PPV = true positive (TP)/TP ? false positive), 
negative predictive value (NPV = true negative (TN)/TN ? false negative) of Aβ-IgM comparing AD patients with the 
healthy control (HC) group 
 
 
3.4 ANTI-Aβ3(pE)-IGM in AD 
 
The general procedure for the screening of naturally occurring autoantibodies (Nabs) in 
the studied groups is summarized in Fig 22 
Preliminary test on all plasma samples for IgM reactivity
to selected peptides
Gelfiltration HPLC on pooled highly-reactive samples, 
fractions collected every 30 seconds
Identification by ELISA of HPLC fractions containing
IgMs
Screening: concentration of IgM is calculated by
interpolation with the standard curve in each ELISA plate
Pooled identified fractions are the standard reference
and are assigned 1000 arbitrary unit/mL
Standard curve is obtained by serial dilutions of standard 
reference
 




The three groups studied for immune complex presence were used to measure the level of 
specific NAbs directed against some relevant Aβ epitopes: plasma samples from 10 
individuals were pooled and analyzed by gel filtration. Fractions collected from the column 
were tested for the presence of anti- Aβ3(pE)-IgM using ELISA assays (Fig. 23). A strong 
immunoreactivity against anti- Aβ3(pE)-IgM was observed in the fractions eluting at high 
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molecular weight (> 500 kDa) (Figure 23A). The fractions contained components migrating 
at the expected molecular weight for reduced IgM that were stained using an anti-human 
IgM antibody (Figure 23B). 
 
 
Figure 23 (A) Gel-filtration HPLC of pooled plasma samples. Proteins are separated according to their molecular 
weight, with the larger proteins eluting first. Total protein concentration of each fraction was measured at 280 nm (grey 
line). The characteristic peaks were as follows: empty volume with a MW>500 kDa (larger proteins and aggregates), 
IgGs with a MW of ~150 kDa, and the albumin peak at~ 66 kDa. A direct ELISA performed on each fraction to 
measure the quantity of anti-Aβ3(pE)-Aβ-IgM (squares) confirms that IgMs elute in the empty volume fractions. (B) 
Western blot against IgM heavy chain in the empty volume fraction. 
 
 
To assess the relevance of these findings, plasma samples from 75 patients with AD, MCI, 
and from healthy controls were analyzed for the presence of natural IgM autoantibodies 
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against different Aβ epitopes. Serial dilutions of the gel filtration-purified IgM fractions have 
been used to draw a reference calibration curve (Figure 24B).  
 
 
Figure 24 (A) Sandwich ELISA: 96-well titer plates are coated with different Aβ fragments (grey). After incubation 
with plasma samples, the wells are washed and incubated with an anti-IgM-heavy chain antibody conjugated with HRP 
(Blue). Signal of bound molecules is therefore only produced by complexes IgMs (red) recognizing that specific 




By interpolation with the standard curve, anti-Aβ-IgM concentration in the plasma samples 
has been expressed in arbitrary units per mL (AU/mL). The titer of IgM autoantibodies 
against Aβ1-42, Aβx-40 and Aβx-42 was not significantly different between AD patients 
and HC (data not shown). The mean level of anti-Aβ3(pE)-IgM was significantly decreased 
in AD patients as compared to healthy controls (3-group ANOVA: F = 3.2, df = 2, 72, p = 
0.045; AD vs. HC: - 29%, p = 0.021). In addition, there was a trend for anti-Aβ3(pE)-IgM 
reduction in MCI patients versus healthy controls (-28%, p = 0.071), while there was no 
significant difference between the two patient groups (AD vs. MCI: -2%, p = 0.92) (Figure 
25 and table 13).  
 
 
Figure 25 (A) Levels of anti-Aβ3(pE)-IgM in the different diagnostic groups. (B) The comparison of the mean values 
shows a significant reduction in AD group compared to HC. (C) ROC curve analysis shows a discrete Area Under the 
Curve (AUC) of 0.68 in discriminating AD and HC samples. By setting sensitivity at a value higher than 80% 
corresponding specificity was 60%. (D) While the anti-Aβ3(pE)-IgM levels correlated significantly with MMSE scores in 




Table 12 Comparison of anti-Aβ3(pE)-IgM between the diagnostic groups. 
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ROC curve analysis of the anti-Aβ3(pE)-IgM showed that specificity was 60% when 
sensitivity was set to 80%, and sensitivity was 32% when specificity was set to 80%, 
comparing AD patients with HC, with an area under the curve (AUC) of 0.68 (Figure 25C, 
Table 14). 
Interestingly, in the group of AD patients there was no significant correlation between anti- 
Aβ3(pE)-IgM and cognitive decline analyzed by MMSE (rho = -0.1, df = 25, p = 0.65). These 
two variables correlated however significantly positive in MCI patients (rho = 0.58, df = 13, 




Table 13 Comparison of specificity, sensitivity, Positive Predictive Value (PPV = true positive (TP)/TP+false positive), 
Negative Predictive Value (NPV = true negative (TN)/TN+false negative) of anti- Aβ3(pE)-IgM assay when setting 

















Beside the two classic hallmarks, amyloid plaques and NFT, AD development is also 
characterized by diffuse Inflammation of the brain, as previously demonstrated in the brain 
of human AD patients showing astrocyte activation (Dickson 1997), as well as microglial 
responses (Rogers et al. 1988; Griffin et al. 1995). 
Considering that in 6 month-old APP/PS1KI mice a profound hippocampal neuron loss, 
accompanied by impairment in cognitive and motor tasks, is detectable, (Casas et al. 
2004; Wirths et al. 2008), aim of this work was to investigate GFAP expression in young 
pre-symptomatic (2 months) and adult (6 months) APP/PS1KI and PS1KI control mice.  
Western blot analysis of protein level in young APP/PS1KI mice revealed an up-regulation 
of GFAP already at 2 months compared to PS1KI controls, and the increase appeared to 
be significantly higher in 6 months-old APP/PS1KI mice.  
This result was in line with quantitative real-time PCR and immunohistochemical staining 
against GFAP and S100A6 in the same mice, showing strong astrogliosis in the 
hippocampus of 6-month-old mice, whereas age-matched PS1KI mice were almost devoid 
of any astroglial reaction (Wirths et al. 2008). These data are consistent with previous 
results obtained in other APP-transgenic mouse models where astro- and microgliosis has 
been consistently reported (Frautschy et al. 1998; Benzing et al. 1999; Bornemann et al. 
2001; Gordon et al. 2002; Richards et al. 2003). Although the relationship between 
extracellular amyloid plaques and astrocytes is not completely clear, recent data suggest 
that astrocytes were able to internalize Aβ peptides, thereby supporting the role of 
astrocytes as active Aβ clearing cells in the central nervous system (Pihlaja et al. 2008). 
In support of a role for inflammation in AD, inflammatory changes have been linked to 
axonal degeneration in a number of other neurodegenerative conditions. In fact, in murine 
experimental autoimmune encephalomyelitis (EAE), an overlap between the earliest 
manifestations of axonal damage and astrocytic responses has been reported (Wang et al. 
2005). Furthermore, in experimental spinal cord injury (SCI) an early up-regulation of 
genes related to inflammation (Ahn et al. 2006), as well as infiltration of blood-derived 
monocytic cells and their morphologic transformation into microglia in zones of acute, 
anterograde (Wallerian) axonal degeneration induced by entorhinal cortex lesion (ECL) 
was reported (Bechmann et al. 2005). 
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In conclusion, this analysis of inflammatory changes in APP/PS1KI mice, coupled with the 
preceding findings in the same mice illustrated in the introduction, indicates early brain 
astroglial activation, which comes along with the first deposition of extracellular plaques 
already at the age of 2 months. Subsequently, when other pathological alterations like 
axonal degeneration, hippocampal neuron loss and behavioural deficits are also evident, 
GFAP expression is further increased, in agreement with the expression of the other 
components of the immune system previously analyzed.  
 
Synaptic deficits 
An emerging role for intracellular Aβ accumulation has been previously shown in human 
AD (Gouras et al. 2000; D'Andrea et al. 2002). It has been observed that Aβ localizes 
predominantly to abnormal endosomes (Cataldo et al. 2004), multivesicular bodies and 
within pre- and postsynaptic compartments (Takahashi et al. 2002; Langui et al. 2004). 
Takahashi et al. (Takahashi et al. 2004) demonstrated that Aβ42 aggregates into oligomers 
within endosomal vesicles and along microtubules of neuronal processes, both in cultured 
Tg2576 neurons, as well as in Tg2576 and human AD brain. Moreover, several other APP 
transgenic mouse models showed impairment of basal synaptic transmission (Hsia et al. 
1999; Moechars et al. 1999; Fitzjohn et al. 2001). 
In this project, strongly reduced levels of pre- and postsynaptic markers in the 
synaptosome fraction have been detected in the same time span where LTP deficits had 
been previously observed (see introduction). Interestingly, only the synaptosome fraction 
displayed such reduction, while the whole brain fraction showed no differences, except for 
post-synaptic density protein PSD-95, which might indicate a stronger pathological effect 
at the post-synaptic site. Notably, Aβ has also been found for the first time to be highly 
enriched in the synaptosome fraction; this finding might indicate a direct link between Aβ 
accumulation and synaptic deficits.  
This group previously observed that different Aβ peptides strongly accumulate within CA1 
neurons in the critical period between 2 and 6 months of age (Wirths et al. 2004); from the 
observation of LTP deficits (see introduction), it has been speculated that there is a narrow 
period for the onset of the synaptotoxic effect, since 4-months-old APP/PS1KI mice and 6-
months-old APP/PS1KI hemizygous mice with only one PS1 knock-in allele show no 
synaptic deficits.  
This coincided with hippocampus atrophy, beginning CA1 neuron loss and synaptic failure, 
thereby linking Aβ accumulation with neurodegenerative mechanisms. These observations 
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also provide additional evidence that Aβ is able to trigger typical neurodegenerative 
mechanisms in AD independent of neurofibrillary tangle formation (Breyhan et al. 2009).  
In conclusion, the data presented here provide evidence that intraneuronal accumulation 
of different Aβ peptides correlates well with a robust dysfunction in synaptic 
functionality/alteration of synaptic functionality in the APP/PS1KI mouse model for AD.  
 
 
4.2 Aβ3(pE)-x IN AD 
 
Considering the increasing importance research is giving to pyroglutamate-modified Aβ 
and the absence of an effective and specific antibody for it, we developed a novel 
monoclonal antibody directed against the N-terminal pyroglutamate modification at position 
3 of Aβ (Aβ3(pE)). Wild type mice have been immunized with an Aβ fragment constituted of 
residues 3 to 7 starting with pyroglutamate to generate antibody-producing hybridoma 
cells. After 2 successive subcloning steps, aimed to purify colonies producing class G 
immunoglobulins (IgGs) of a single subclass, the 2 subclones showing the best 
characteristics of sensitivity and specificity in dot-blot and IHC experiments have been 
selected. The antibodies showed the capacity to stain large numbers of plaques positive 
for Aβ3(pE) patients with sporadic and familial AD including those carrying mutations in APP 
(arctic and Swedish). The specificity was confirmed by dot-blot experiments comparing 1-
57 and 2-48 with a generic anti-Aβ-antibody (WO-2, residues 5-8), an antibody directed 
against the native N-terminus of Aβ and a commercially available anti-Aβ3(pE)-x. The dot 
blot experiment showed no reactivity to both full-length native Aβ and unmodified Aβ 
starting at residues 3. Antibodies 1-57 and 2-48 have been contemporarily further 
characterized in other experiments. Avidity for each antibody was calculated by BIAcore 
(GE Healthcare, Uppsala, Sweden), obtaining KD-values of 17.7 nM for 1-57 and 9.1 nM 
for 2-48, which confirmed a very high affinity for both antibodies (Wirths et al. 2009). In an 
SDS-PAGE experiment (Wirths et al. 2009) under denaturing conditions the two antibodies 
specifically detected Aβ3(pE)-42 without any visible cross reactivity against other Aβ epitopes 
and not even against N-truncated Aβ starting with a pyroglutamate modification at residue 
11. Finally, by immunohistochemical staining of human brain slices, it has been showed 
that large numbers of plaques positive for Aβ3(pE) are present both in patients with sporadic 
AD and with familial AD. The amount of plaques positive for Aβ1-x  is less abundant in the 
control cases. Interestingly, in APP/PS1KI there is a continuous increase in Aβ 3(pE) plaque 
load with increasing age, while the density for Aβ1-x plaques declined with aging. It is 
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therefore possible to assume that in particular the peptides starting with position 1 of Aβ 
are N-truncated as disease progresses (Wirths et al. 2009). 
N-truncated Aβ3(pE) peptides have been identified by several groups from AD brains (Mori 
et al. 1992; Saido et al. 1995; Iwatsubo et al. 1996; Saido et al. 1996; Kuo et al. 1997; 
Russo et al. 1997; Hosoda et al. 1998; Tekirian et al. 1998; Harigaya et al. 2000; Kuo et al. 
2001; Miravalle et al. 2005; Piccini et al. 2005; Guntert et al. 2006; Piccini et al. 2007) and 
they have been reported to be the dominant Aβ species in AD brain (Saido et al. 1995). In 
addition, other N-terminal truncated peptides have been identified such as Aβ5–40/42 
(Takeda et al. 2004), Aβ11–40/42 (Lee et al. 2003; Liu et al. 2006), and Flemish and Dutch N-
terminally truncated Aβ peptides (Demeester et al. 2001). 
Although the precise formation process and the regulation of Aβ3(pE) are at the moment 
unknown, Saido et al. suggested that the removal of Aβ N-terminal amino acids 1 and 2 
could be carried out by a hypothetical peptidase (Saido et al. 1995); in this regard it has 
been very recently shown that aminopeptidase-A may be responsible for the N-terminal 
truncation of the aspartate at position 1 of full-length Aβ (Sevalle et al. 2009).  
In in vitro experiments Schilling et al. have shown that cyclization of glutamate at position 3 
can be driven enzymatically by glutaminyl cyclase (QC) (Schilling et al. 2004). In addition, 
it has been shown that QC inhibition significantly reduced Aβ3p(E) formation in vitro and in 
vivo, emphasizing the importance of QC activity during cellular maturation of 
pyroglutamate-containing peptides (Cynis et al. 2006; Schilling et al. 2008). It has been 
postulated that pyroglutamate may protect the peptide from exopeptidase degradation and 
make it more prone to accumulate, thus explaining the observed 250-fold increased 
acceleration of the initial formation of Aβ aggregates (Schilling et al. 2006) and increased 
toxicity compared to full-length Aβ (He et al. 1999; Russo et al. 2002). 
To further verify this in vivo, this group has recently generated transgenic mice expressing 
Aβ starting at position 3 with glutamine and ending at position 42 (TBA2 mouse line ) 
(Wirths et al. 2009). This model showed for the first time that intraneuronal Aβ3(pE)–42 
accumulation is sufficient for triggering neuron death and inducing an associated 
neurological phenotype in a transgenic mouse model. The severity of the neurological 
phenotype observed in TBA2 mice, accompanied by Purkinje cell loss and premature 
mortality reflects the in vivo toxicity of Aβ3(pE)-42. Aβ staining in the cerebellum was 
completely restricted to the intraneuronal compartment further supporting the notion that 
intraneuronal pathology is instrumental in neuron loss and that extracellular plaque 
deposition has no drastic effect on cell survival.  
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4.3 AD BIOMARKERS 
 
 
4.3.1 PREVENTION AND DIAGNOSIS 
 
Today’s few available options for AD have the only effect of slowing down the progress of 
the disease for a few months, as can be expected considering the neurodegenerative 
nature of the disease. Moreover, even though the clinical symptoms of AD are detectable 
at an advanced age, the molecular processes leading to AD start up to 20 years before the 
onset of the first symptoms. For these reasons AD treatment must necessarily act on 
early, asymptomatic phases of the disease; it would therefore be more useful to develop 
preventive, rather then therapeutic, treatment.  
The most obvious way to deal with AD prevention is to act on modifiable risk factors. Not 
so long ago, the traditional risk factors for AD (advanced age, familial aggregation and the 
APOE ε4 allele) kept prevention somewhere at the bottom of the list of priorities in AD 
research and in clinical practice. However, during the recent years, evidence has 
accumulated from long-term population-based studies that several modifiable risk factors 
(especially vascular and lifestyle-related), besides their customary association with 
cardiovascular disease, are also important for AD. The genetic constitution of an individual 
is currently non-modifiable, but interactions between genetic susceptibility and 
environmental factors create opportunities for preventing diseases of multifactorial origin, 
such as AD.  
Like for many other chronic diseases, efficient AD prevention can only be achieved by 
taking a life-long view of the disease. High blood pressure, especially at midlife, has been 
associated with an increased AD risk later in life (Launer et al. 2000; Kivipelto et al. 2002). 
It has been reported that high serum total cholesterol values at midlife increase the risk of 
late life AD (Kivipelto et al. 2002; Whitmer et al. 2005). A diet rich in saturated fats and 
cholesterol may also increase the risk of AD, whereas polyunsaturated fatty acids and fish 
seem to be protective. However, contradictory findings exist as well (Luchsinger et al. 
2004).  
Another lifestyle-related factor which has been suggested to be connected with AD is 
physical activity. Some shorter term longitudinal studies indicated an inverse association 
between regular and high intensity leisure time physical activity, or some specific form of 
physical activity (e.g. dancing, walking) and dementia/AD risk, whereas other found no 
association (Fratiglioni et al. 2004). Social and mental activities have also been suggested 
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to protect against AD (Fratiglioni et al. 2004); however, none of these findings has been 
consistently proven.  
 
 
4.3.2 CURRENT SEROLOGICAL BIOMARKERS FOR AD 
 
Clearly, any prevention strategy could be more easily targeted if coupled to an efficient tool 
for early diagnosis of AD. At present, only CSF Aβ and Tau level are well established AD 
biomarkers with high sensitivity and specificity (Galasko 1998; Kanai et al. 1998; Tapiola et 
al. 2000; Andreasen et al. 2001; Lewczuk et al. 2004). Although much better for clinical 
practise, blood Aβ measurement is controversially discussed as a useful biomarker for AD. 
Unfortunately, there seems to be no correlation between CSF and blood Aβ level, as 
shown by several groups (Mehta et al. 2000; Vanderstichele et al. 2000; Mehta et al. 2001; 
Matsumoto et al. 2007). Studies have shown a decreased blood level of Aβ in AD subjects 
(Pesaresi et al. 2006; Xu et al. 2008), while others showed an increase (Kosaka et al. 
1997; Matsubara et al. 1999), or no statistical differences (Tamaoka et al. 1996; Fukumoto 
et al. 2003).  
The same inconsistency emerged from a series of prospective studies, in which a higher 
risk for developing AD has been associated both with higher baseline plasma Aβ42 
concentration (Pomara et al. 2005) or higher Aβ40 with no effect on Aβ42 (van Oijen et al. 
2006). Finally, Graff-Radford et al. (Graff-Radford et al. 2007) linked a high risk for 
developing AD to a lower Aβ42/Aβ40 ratio.  
 
 
4.3.3 IMMUNE COMPLEXES 
 
Recently, ICs of known cancer biomarkers with IgM have attracted investigators’ attention 
because they have been proven to correlate better than unbound biomarkers with 
pathology in different cancer types (Beneduce et al. 2005; Castaldi et al. 2005; Beneduce 
et al. 2007; Beneduce et al. 2008), characterized by an over- or mis-production of an 
endogenous protein. 
It is well known that IgM complexes are in equilibrium in blood with the unbound respective 
antigen; it is reasonable to think that the same equilibrium holds true for any IgM complex 
in blood. Already established ICs as biomarkers include: PSA–IgM for prostate cancer 
(Beneduce et al. 2007), carcinoembryonic antigen–IgM for colorectal cancer (Castaldi et 
 84
al. 2005) alpha fetoprotein–IgM and squamous cell carcinoma antigen-IgM for liver cancer 
(Beneduce et al. 2004; Beneduce et al. 2005). Moreover, IgM ICs have also been shown 
to be uncorrelated with basal IgM levels (Beneduce et al. 2008). Nydegger (Nydegger 
2007) discussed in a review article biochemical properties of immune complexes in 
general, their formation and their equilibrium state, stating that immune complex IgM-
antigen interaction is extremely high compared to other biochemical interactions.  
Goals of this study were to verify the occurrence of ICs of Aβ and IgM in the plasma of AD 
and MCI patients and HC, in order to evaluate a possible correlation between the IC level 
and AD. 
Plasma samples from 30 AD patients, 15 MCI patients, and 30 age- and sex-matched HC 
have been analyzed to determine the levels of circulating Aβ–IgM ICs. After proteins have 
been separated and purified by size-exclusion gelfiltration, Aβ was primarily found to be 
associated with the IgM and the IgG fractions using a dedicated ELISA assay. This is the 
first characterization of circulating Aβ–IgM complexes in AD. The Aβ–IgM assay did not 
show any significant difference among the three groups, in contrast with previous findings 
(Gruden et al. 2007), proving that although there is great interest around autoimmunity in 
AD, IC levels cannot be used as a diagnostic marker. It should be noted, however, that 
variability of IC level was high within the groups. This high variance leading to an overlap 
between AD patients and HC might be partly due to biological variability.  
Consensus criteria for a suitable biomarker (Trojanowski et al. 1998) for AD were not met. 
On the other hand, the presence of circulating ICs against neuronal antigens supports the 
notion that autoimmune- mediated processes may be involved in neurodegenerative 
disorders. Further investigations are needed to elucidate the pathophysiologic role of these 
complexes; it will be interesting in particular to evaluate in future studies possible 
relationships of Aβ-IC levels with the clinical development of MCI patients, and with AD 
patients’ response to immune therapies. 
 
 
4.3.4 ANTI-Aβ3(pE)-IgM NATURAL ANTIBODIES 
 
4.3.4.1 PREVIOUS STUDIES ON NATURAL ANTIBODIES IN AD 
Naturally occurring anti-Aβ antibodies were first isolated from human B cells (Gaskin et al. 
1993); since then several epidemiologic studies have confirmed the presence of anti-Aβ 
NAbs in the blood of both AD patients and HC, although with contradictory results. 
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To evaluate a possible use as biomarkers for AD, levels of NAbs against Aβ1-40 and Aβ1-42 
have been measured both in mice ((Nath et al. 2003; Li et al. 2007; Sohn et al. 2007) and 
humans (Gaskin et al. 1993; Hyman et al. 2001; Nath et al. 2003; Henkel et al. 2007; 
Gustaw et al. 2008; Szabo et al. 2008) but as of today there is no agreement whether 
there is a difference between AD patients and HC. Depending on the study, titer of anti-
Aβ42 autoantibodies was reported to be lower in AD patients compared to healthy 
individuals (Du et al. 2001; Weksler et al. 2002), higher (Nath et al. 2003); another study 
reported no correlation between autoantibodies titers and plasma Aβ40 or Aβ42 levels 
(Hyman et al. 2001).  
More recent studies focusing on autoantibodies against oligomeric forms of Aβ have also 
given contradictory results, with some studies reporting a lower immunoreactivity in AD 
patients compared to HC (Moir et al. 2005), while others showed a higher titer (Gruden et 
al. 2007) or no significant differences (Britschgi et al. 2009). 
 
 
4.3.4.2 ANTI- Aβ3(pE)-IgM LEVELS 
 
The goal of the present study was to characterize the occurrence of IgM autoantibodies 
against Aβ in the same samples used for the IC project, and to evaluate a possible 
correlation between the immunological profiles of individuals with AD.  
The same plasma samples used for the IC project have been analyzed to determine the 
levels of circulating Aβ-IgM. After gel-filtration and size fractionation, high reactivity against 
the Aβ3(pE)-7 peptide was found in the IgM fractions using a dedicated novel ELISA assay. 
A significant decrease in the level of autoantibodies against Aβ3(pE)-x was observed in AD 
patients as compared to HC. To note, the MCI group showed a mean level of anti-Aβ3(pE)-x-
IgM in between that of the AD group and of the HC, even though it didn’t differ significantly 
from them, reflecting the heterogeneous and intermediate nature of the group; 
interestingly, in the MCI group there was a significant positive correlation between anti-
Aβ3(pE)-x-IgM and cognitive status (MMSE score). None of the other IgM autoantibody 
levels against Aβ showed any significant difference between the groups. These results 
indicate that circulating Aβ3(pE)-x-IgMs result from autoimmune mediated processes 
involved in AD. However, whether this immune activity is defensive or toxic is still a matter 
of debate (Woulfe et al. 2002; Nath et al. 2003; Geylis et al. 2005); in any case, 
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autoimmunity driven homeostasis of plasma protein levels is a natural process and its 
understanding may be useful in both diagnosing and treating AD.  
The fact that only anti-Aβ3(pE)-x-IgMs show difference between the groups gives further 
support to the pathological role proposed for the pyroglutamate-modified peptide. As it has 
recently been shown by this group, Aβ3(pE)-positive plaques are abundant in sporadic and 
familial AD cases, and at least in the APP/PS1KI mouse model, the Aβ3(pE)-x plaque load 
increases in an age-dependent manner, which is not the case for total Aβ and Aβ1-x 
(Wirths et al. 2009). 
The exact role of NAbs in AD is still not clear; a possibility includes that they serve as a 
‘‘buffering system’’ to keep free potential toxic endogenous peptides and proteins under 
homeostatic control and lead to their clearance (Gruden et al. 2007); according to this 
idea, a lower clearance activity by NAbs would facilitate Aβ, and pyroglutamate-modified-
Aβ in particular, accumulation and aggregation. In support to this homeostatic role, there 
are experimental evidences of anti-Aβ-IgM NAbs able to catalyze hydrolysis of Aβ peptide 
(Taguchi et al. 2008), and to promote clearance of Aβ plaques (Dodel et al. 2003), as 
shown in neuronal cell cultures (Du et al. 2003) and animal models of amyloid pathology 
(Wilcock et al. 2003).  
 
 
4.3.4.3 FUNCTION OF IGM NABS IN ATHEROSCLEROSIS 
 
The results presented here, together with the positive results from immunotherapy studies, 
allow speculation on a possible role as housekeeping agents for NAbs in AD. On this 
subject, it may be interesting to look at NAbs in atherosclerosis, whose role is better-
known, and speculate on a possible analogy with AD.  
Like AD, atherosclerosis is also a slow, continuously developing disease, evolving from 
intimal thickening to increasingly complex lesions, consisting of cells derived from the 
circulation, wall cells, but also of extracellular matrix material and lipoproteins (LDL). 
Oxidized-LDL (OxLDL) are recognized and bound by natural anti-OxLDL-IgGs; successive 
excess uptake by macrophages results in foam cell formation within atherosclerotic 
plaques which lead to pathological inflammation. Tsimikas et al found a lower anti-OxLDL-
IgM level and a higher IgG level in the blood of patients at risk for coronary stenosis 
(Tsimikas et al. 2007), while Su et al found a direct correlation of anti-OxLDL-IgM with 
decreased risk of carotid atherosclerosis in hypertensive patients (Su et al. 2006).  
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As a further evidence, mice immunized with heat-killed phosphorylcholine-containing 
pneumococci have a high titer of anti-OxLDL IgM and show reduced formation of 
atherosclerotic lesions (Binder et al. 2003). Similarly, passive immunization with the same 
antibodies lead to reduced lesion formation (Faria-Neto et al. 2006). In both cases, IgM 
seem to carry out this atheroprotective effect by binding OxLDL and thus neutralizing its 
pro-inflammatory effects and inhibiting its uptake by macrophages (Horkko et al. 1999; 
Chang et al. 2004).  
Considering the toxic nature of self peptides also in AD, and the related inflammatory 
events, we suggest a similar protective role for IgM. Moreover, the opposite roles of IgMs 
and IgGs in atherosclerosis may also explain the contradictory results in previous studies 
on anti-Aβ-NAbs in AD, which were mostly based on IgGs only or total Igs titer 
measurement ((Binder et al. 2005) for a review). 
Recently, a very detailed study on autoantibodies directed against many different Aβ forms 
has been published (Britschgi et al. 2009) which also shows an abundant titer of NAbs 
directed in particular against post-translationally-modified Aβ. The authors found a 
decreasing titer of NAbs with age, although no differences between AD patients and HC 
have been found. However, it is to note that the analysis of plasma autoantibodies has 
been limited to IgGs. The latter also show to be protective in vitro on cultured neurons; 
clearly, pro-inflammatory effects could not be evaluated in such an experiment. 
 
 
4.3.4.4 ANTI-Aβ ANTIBODIES IN THERAPY 
 
APP transgenic mice injected intravenously with monoclonal anti-Aβ antibody showed a 
rapid and massive increase of CNS-derived Aβ in the plasma, further suggesting that 
antibodies may participate in Aβ clearance from the brain (DeMattos et al. 2001).  
The mechanism proposed for this immune-mediated elimination of Aβ is that natural 
antibodies bind Aβ in the blood, thus reducing its effective free concentration. This leads to 
increase the concentration gradient between brain and blood, enhancing efflux 
mechanisms’ effectiveness in clearing Aβ out of the brain. 
This idea has been recently challenged with a surprising result from Yamada et al. After 
intraperitoneal injection of anti-Aβ or control anti-α-synuclein murine antibodies, the 
authors microinjected radioactive Aβ1-40 into the brain of mice and by monitoring the 
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radioactivity they showed that clearance of Aβ from the brain was slower in mice injected 
with anti-Aβ when compared to the controls (Yamada et al. 2009). 
There are evidences for a therapeutic use of anti-Aβ antibodies in human, as it is being 
shown by current experimental immunotherapeutic approaches. Hock et al. showed that 
active immunization against aggregated Aβ42 resulted in a slower cognitive decline in a 
dose-dependent fashion. Patients generating a higher titer of anti-Aβ-antibodies performed 
better in cognitive tests than patients who did not respond to the immunization protocol 
(Hock et al. 2003). In this study, the increase in antibody titer did not correspond to a 
decrease in Aβ blood levels; in contrast, significant changes were observed in serum and 
CSF of patients with AD after treatment with intravenous anti-Aβ-IgGs (Dodel et al. 2002). 
The levels of Aβ autoantibodies of the IgG class for monitoring the effect of passive or 
active immunization in AD have already been evaluated by recent studies. It is speculative 




4.3.4.5 NAbs REGULATION 
 
It is important to evaluate whether and how IgM production is regulated, in order to 
understand whether NAbs can be considered as a biomarker or rather as a risk factor. IgM 
is a protein constitutively produced by the B-1 subset of B-cells. There is a number of 
factors which have been found to influence the production of IgMs. TLR9 induces a signal 
cascade that ultimately activates NF-kB to promote the transcription of several molecules 
including CD38 and IgM in B-cells (Peng 2005). In primary biliary cirrhosis, 
hyperproduction of IgM from B-cells is induced by stimulation of TLR9 by bacterial CpG 
oligodeoxynucleotides (Kikuchi et al. 2005), indicating that IgM production can be induced 
as a reaction to a noxious challenge. IgM production can also be altered in vivo by 
chemical substances such as ursodeoxycholic acid (UDCA). UDCA reduces IgM 
production possibly by reducing cell activation and down-regulating the NF-kB intracellular 
signalling pathway (Kikuchi et al. 2009).  
Normal antigens binding on surface IgMs do not trigger B-1 cells antibody responses; 
however, certain antigenic stimuli, like phosphorylcholine in the context of an appropriate 
carrier can induce antibody response, although it does not lead to the generation of 
memory cells.  
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B-1 cells have been found to be stimulated in their maturation and IgM secretion by 
interleukin-5 (IL-5), which mediates also the expansion of type T15 and EO6 natural IgM in 
mice (Takatsu 1998; Moon et al. 2004). Additionally, several Th2 cytokines, such as IL-9 
and IL-10 have also been reported to participate in B-1 cells development and function 
(Nisitani et al. 1995; Vink et al. 1999). Mutations that disrupt positive regulators of BCR 
signalling, such as CD19, PI-3K p85, vav, BTK, or CR1/CR2, result in decreased B-1 cell 
numbers, while mutations in inhibitory regulators such as SHP-1, CD22, CD72 or Lyn, can 
lead to increased B-1 cell numbers (Berland et al. 2002). 
In murine models of autoimmune diseases, it has been found that genetic factors 
contribute to determine B-1 cells compartment size, and a series of loci has been identified 
which are linked to B-1 cells expansion (Hayakawa et al. 1986; Hamano et al. 1998; Pers 
et al. 2002; Li et al. 2004). It is possible to speculate that like a lowered activation 
threshold against physiological self-antigens leads to autoimmune disease, so a similar 
mechanism against pathological self-antigens may lead to increased protection. It’s 
possible to imagine a genetic background with a lowered activation threshold for B-1 cells, 
inducing proliferation and NAbs secretion in response to normally sub-threshold activation 
signals; oppositely, an increased activation threshold would decrease NAbs production 















Synaptic and inflammatory markers 
Quantitative western blot of different synaptic and inflammatory markers on APP/PS1KI 
mice evidenced how the pathology in these mice reflects for many characteristics the 
pathology in human patients. Synaptic dysfunction seems to be initiated between 2 and 6 
months, the same period where neuron loss starts; however, the inflammatory marker 
GFAP has been found over-expressed already at 2 months. These finding may suggest 
that inflammatory events precede and possibly contribute to neuron loss. This is consistent 
with the observation that Aβ is enriched in the synaptosome fraction, giving a further 
indication that Aβ carries out its pathological effect by acting directly at the synaptic level. 
 
Monoclonal anti-pyroglutamate antibodies 
The two antibodies developed in this work showed a striking specificity and a good 
sensitivity, especially when compared in a dot blot experiment to a commercially available 
antibody directed against the same epitope. There is no cross-reaction detected 
whatsoever with other unmodified Aβ fragments; hence they represent a valuable tool for 
the study of Aβ3(pE)-x. 
 
AD blood biomarkers 
The failure to obtain the same results seen in cancer with the measurement of IC in AD 
can be due to at least two main reasons. First, it was not possible to measure IC of 
specific Aβ subpopulations, including Aβx-42 or Aβ3(pE)-x, since the epitopes are masked by 
the bound IgM. Therefore, only measurement of total Aβ in complex with IgMs was 
possible, this excludes the possibility of revealing a specific recognition by IgM of those Aβ 
forms that in sporadic AD appear to be more relevant in causing neuronal dysfunction. 
Secondly, ICs level in cancer is probably higher as a consequence of the fact that the 
number of antigen-producing cells is increased. In AD, increase in Aβ production seems to 
account for only a small minority of cases, specifically those bearing inherited mutations in 
APP or PS1/2; this may suggest that many AD cases are caused by a faulty clearance of 
Aβ, rather than by its overproduction. Proteins involved in Aβ clearance are, among 
others, apolipoprotein E (whose allele E4 is less effective in clearing Aβ), proteases like 
neprilysin and insulin-degrading enzyme and NAbs against Aβ ((Selkoe 2001) for review). 
Measuring specific IgM NAbs, rather than ICs, made it possible to bypass these issues.  
The finding that anti-Aβ3(pE)-NAbs level is lower in AD patients, while ICs are not changed, 
may indicate that a low level of this autoantibody could be a situation preceding the clinical 
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symptoms of AD, rather than being a consequence of AD development; in this case it 
would acquire a predictive value for AD. It can be speculated that less efficacy in 
clearance of Aβ3(pE) by IgM concurs in favouring its accumulation both intracellularly and in 
the amyloid plaques.  
It is not clear, however, whether and how natural IgMs levels are regulated, in particular in 
regard to the development of the disease. A better understanding of its regulation will also 
help to determine whether anti-Aβ3(pE)-IgM NAbs are a biomarker or a risk factor for AD. In 
this respect, it will be interesting to evaluate the levels of anti-Aβ3(pE)-IgM level in a 
prospective study on AD and MCI patients and HC. (2009) 
Measurement of anti-Aβ3(pE)-IgM has proven to be a valuable tool for the study of AD in 
vivo in humans, with potential applications ranging from diagnosis, therapy and monitoring 
of the disease; the findings of this work have also the potential to shed light on the 
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